Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
WO 2021/047648
PCT/CN2020/114828
NEW PEPTIDES
Field of the Invention
This invention relates to new, short-chain oligopeptides, the use of such
peptides in
human medicine, and to pharmaceutical compositions comprising them. In
particular,
the invention relates to the use of those peptides and compositions in the
treatment of
e.g. inflammation.
Background and Prior An
Inflammation is typically characterized as a localised tissue response to e.g.
invasion
of microorganisms, certain antigens, damaged cells or physical and/or chemical
factors.
The inflammatory response is normally a protective mechanism which serves to
destroy, dilute or sequester both the injurious agent and the injured tissue,
as well as
to initiate tissue healing.
Inflammation may result from physical trauma, infection, some chronic diseases
(e.g.
psoriasis and autoimmune diseases, such as rheumatoid arthritis) and/or
chemical
and/or physiological reactions to external stimuli (e.g. as part of an
allergic response).
A complex series of events may be involved, in which inflammatory mediators
increase
blood flow and dilation of local blood vessels, resulting in redness and heat,
the
exudation of fluids, often resulting in localised swelling, leukocytic
migration into the
inflamed area, and pain.
Many conditions/disorders are characterized by, and/or are caused by,
abnormal,
tissue-damaging inflammation. Such
conditions are typically characterized by
activation of immune defence mechanisms, resulting in an effect that is more
harmful
than beneficial to the host, and are generally associated with varying degrees
of tissue
redness or hyperemia, swelling, hyperthermia, pain, itching, cell death,
tissue
destruction, cell proliferation and/or loss of function. Examples include
inflammatory
bowel diseases, rheumatoid arthritis, multiple sclerosis, psoriasis,
glomerulonephritis
and transplant rejection.
Typically, a complex series of events results in inflammatory changes such as
increased
blood flow through dilation of local blood vessels, resulting in redness and
heat, the
extravasation of leukocytes and plasma, often resulting in localised swelling,
activation of sensory nerves (resulting in pain in some tissues) and loss of
function.
1
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
These inflammatory changes are triggered by a cascade of cellular and
biochemical
events involving cells like neutrophils, monocytes, macrophages and
lymphocytes
together with inflammatory mediators such as vasoactive amines, cytokines,
complement factors and reactive oxygen species.
Amongst other things, inflammation plays a key role in the wound healing
process.
Wounds and burns can therefore be classified as conditions with which
inflammation is
associated. Traditional thinking in the art is that anti-inflammatory drugs
should not
be applied directly to open wounds, as this would be detrimental to the
progress of
wound healing.
Fibrosis is defined by the excessive accumulation of fibrous connective tissue
(components of the extracellular matrix (ECM) such as collagen and
fibronectin) in and
around inflamed or damaged tissue. Although collagen deposition is typically a
reversible part of wound healing, it can often evolve into a progressively
irreversible
fibrotic response if tissue injury is severe, or if the wound-healing response
itself
becomes dysregulated. Furthermore, fibrogenesis is known to be a major cause
of
morbidity and mortality in many chronic inflammatory diseases, as well as end-
stage
liver disease, kidney disease, idiopathic pulmonary fibrosis (IPF) and heart
failure. It
is also a pathological feature of many chronic autoimmune diseases, such as
scleroderma, rheumatoid arthritis, Crohn's disease, ulcerative colitis,
myelofibrosis and
systemic lupus erythematosus. Fibrosis may also influence the pathogenesis of
many
progressive myopathies, metastasis and graft rejection.
Mussel adhesive protein (MAP), also known as Mytilus edulis foot protein
(mefp), is a
protein that is secreted by marine shellfish species, such as Mytilus edulis,
Mytilus
coruscus and Perna viridis. Eleven identified separate adhesive protein
subtypes have
been derived from mussels, including the collagens pre-COL-P, pre-COL-D and
pre-
COL-NG; the mussel feet matrix proteins PTMP (proximal thread matrix protein)
and
DTMP (distal thread matrix protein); and mfp proteins mfp-2 (sometimes
referred to
as "mefp-2", hereinafter used interchangeably), mfp-3/mefp-3, mfp-4/mefp-4,
mfp-
5/mefp-5, mfp-6/rnefp-6 and, most preferably mfp-1/mefp-1 (see, for example,
Zhu
et al, Advances in Marine Science, 32, 560 (2014) and Gao et al, Journal of
Anhui Agr.
&I., 391 19860 (2011)).
A significant portion of mefp-1 consists of 70 to 90 tandem repeats of the
decapeptide:
Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (SEQ ID No: 1; see Waite, Int. J.
Adhesion and Adhesives, 7, 9 (1987)). This decapeptide sequence may be
isolated
2
CA 03150864 2022-3-10 RECTIFED SHEET (
RULE 91 )
WO 2021/047648
PCT/CN2020/114828
as a low molecular weight derivative of naturally-occurring MAPS, or may be
synthesized, for example as described by Yamamoto in J. Chem. Soc., Perkin
Trans. 1,
613 (1987). See also Da!sin et of, J. Am. Chem. Soc., 125, 4253 (2003).
5 Analogues of the decapeptide, notably Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-
Lys (SEQ
ID No: 2) have also been disclosed. See, for example, US 5,616,311 and WO
96/39128.
There is a clear need for new and/or improved medicines that may be used in
the
10 treatment of inflammation and conditions characterised thereby.
Disclosure of the Invention
According to a first aspect of the invention, there is provided an (isolated)
peptide
15 compound of the amino acid sequence:
G-W-Lys-X'-Ser-U-X2-Y-Z-Q (SEQ ID No: 3)
wherein:
20 G represents an optional N-terminal a 3,4-dihydrocinnamic acid group;
W represents Ala or Ser, or is absent (in which case, Lys is the N-terminal
amino acid);
U represents Tyr, DOPA or a single bond (i.e. is absent);
X1 and X2 independently represent Pro, Hyp or diHyp;
Y represents a single bond (i.e. is absent) or represents a 1 to 5 amino add
sequence,
25 in which the amino acids are selected from one or more of the group Pro,
Hyp, diHyp,
Thr, DOPA and Tyr;
Z represents Pro, Hyp, diHyp, Thr, DOPA or Tyr; and
Q represents Lys or is absent (in which case Z represents the C-terminal amino
acid),
as well as regioisomers, stereoisomers, and pharmaceutically- or cosmetically-
30 acceptable salts of said peptide compound,
provided that when G is not present, W represents Ala or is absent and Q
represents
Lys, then Z represents Pro, Hyp, diHyp or Thr (i.e. Z does not represent DOPA
or Tyr),
which compounds, regioisomers, stereoisomers and salts are referred to
together
hereinafter as 'the compounds of the invention'.
Compounds of the invention that may be mentioned include those in which:
G is not present;
X1 represents Pro;
3
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
X2 represents Pro or Hyp;
Y represents a single bond (i.e. is absent) or represents a 1 to 5 amino acid
sequence,
in which the amino acids are selected from one or more of the group Pro, Hyp,
Thr,
DOPA and Tyr; and/or
5 Z represents Pro, Hyp, Thr, DOPA or Tyr.
Preferred compounds of the invention include those in which
U represents DOPA or, more preferably Tyr;
X1 represents Hyp or, more preferably, Pro;
10 X2 represents diHyp or, more preferably, Hyp;
Y represents a 1 to 4, such as a 3, 1 or, preferably, 2 amino acid sequence,
in which
the amino acids are selected from the group Pro, Hyp, Thr, DOPA and Tyr.
Peptide compounds of the invention that may be mentioned include those in
which W
15 represents Ser.
However, more preferred compounds of the invention include those in which W is
absent or, more preferably, W represents Ala.
20 Preferred compounds of the invention also include those in which Q
represents Lys.
More preferably, compounds of the invention also include those in which Z
represents
DOPA or Tyr, more preferably Pro or, especially, Hyp.
25 Preferred compounds of the invention also include those in which, when Q
represents
Lys, Z represents DOPA or Tyr, more preferably Pro or, especially, Hyp.
Further preferred compounds of the invention include those in which the amino
acids
in the sequence defined by Y are selected from Pro, preferably DOPA, more
preferably
30 Hyp, Thr and Tyr.
Especially preferred compounds of the invention include those in which, in the
sequence defined by Y:
the amino acid DOPA, preferably Thr or, more preferably, Tyr is linked to Z;
35 the amino acid Pro, or more preferably Hyp or Thr is linked to X2.
Preferred values of Y include, when it is a 3-membered amino acid sequence, -
Hyp-
Thr-Tyr or, more preferably ¨Hyp-Thr-DOPA-, and, when it is a 2-membered amino
4
CA 03150864 2022-3-10 RECT1FED SHEET (
RULE 91 )
WO 2021/047648
PCT/CN2020/114828
acid sequence, -Thr-Tyr- or, more preferably, -Thr-DOPA-, or -Pro-Thr- or,
more
preferably, -Hyp-Tbr-.
Compounds of the invention that may be mentioned include those of the amino
acid
sequence:
Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 4);
Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 5);
Lys-Pro-Ser-Tyr-Hyp-Tbr-DOPA-Hyp-Lys (SEQ ID No: 6); and
Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 7).
Preferred compounds of the invention include those of the amino acid sequence:
Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (SEQ ID No: 8);
Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 9);
Ser-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 10);
Ser-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 11).
More preferred compounds of the invention include those of the amino acid
sequence:
Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 12);
Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 13); more preferably
that
defined by the amino acid sequence:
Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 14); and
particularly that defined by the amino acid sequence:
Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 15).
Further compounds of the invention that may be mentioned include those in
which Q
is absent, such as those of the amino acid sequence:
Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp (SEQ ID No: 16);
Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp (SEQ ID No: 17);
Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp (SEQ ID No: 18);
Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp (SEQ ID No: 19);
Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr (SEQ ID No: 21);
Ser-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp (SEQ ID No: 22);
Ser-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp (SEQ ID No: 23);
Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp (SEQ ID No: 24);
Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp (SEQ ID No: 25);
Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp (SEQ ID No: 26);
Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp (SEQ ID No: 27); and
particularly, that defined by the amino acid sequence:
5
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Tbr-DOPA (SEQ ID No: 20).
Further compounds of the invention in which G is an N-terminal 3,4-
dihydrocinnamic
acid, include that defined by the amino acid sequence:
5 3,4-dihydrocinnamic acid-Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID
No: 28);
and, more preferably, that defined by the amino add sequence:
3,4-dihydrocinnamic acid-Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No:
29).
10 Further preferred compounds of the invention mentioned include those in
which W is
Ala and Q is Lys, such as those of the amino acid sequence:
Ala-Lys-Pro-Ser-CiOPA-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 30);
Ala-Lys-Pro-Ser-Pro-Thr-Tyr-Pro-Lys (SEQ ID No: 31);
Ala-Lys-Hyp-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 32);
15 Ala-Lys-Hyp-Ser-DOPA-Hyp -Thr-DOPA-Hyp-Lys (SEQ ID No: 33); and
particularly, that defined by the amino acid sequence:
Ala-Lys-Hyp-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 34)
Further compounds of the invention that may be mentioned include those in
which Q
20 is absent, such as those of the amino acid sequence:
3,4-dihydrocinnamic acid-Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr (SEQ ID No: 35);
3,4-dihydrocinnamic acid-Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp (SEQ ID No: 36);
Ala-Lys-Pro-Ser-DOPA-Hyp-Thr-DOPA-Hyp (SEQ ID No: 37);
Ala-Lys-Pro-Ser-Pro-Thr-Tyr-Pro (SEQ ID No: 38);
25 Ala-Lys-Hyp-Ser-Tyr-Hyp-Thr-Tyr-Hyp (SEQ ID No: 39);
Ala-Lys-Hyp-Ser-DOPA-Hyp -Thr-DOPA-Hyp (SEQ ID No: 40); and
Ala-Lys-Hyp-Ser-Tyr-Hyp-Thr-DOPA-Hyp (SEQ ID No: 41)
As described hereinafter, it is understood that certain compounds of the
invention,
30 induding those in which, for example, Q is Lys, and/or in which W is Ser
and/or Z is
Pro or, particularly Hyp, and, in particular, compounds of the invention
comprising
amino acid sequences SEQ ID No: 4 to SEQ ID No: 15, and SEQ ID No: 28 to SEQ
ID
No: 34 are resistant to metabolism.
35 Nevertheless, the skilled person will appreciate that metabolites of
compounds of the
invention that may be formed following administration are included within the
scope of
the invention.
6
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
In particular, compounds of the invention in which Q is absent, including
those with
amino acid sequences SEQ ID No: 16 to SEQ ID No: 27, and SEQ ID No: 35 to SEQ
ID
No: 41, respectively, may be formed as metabolites of corresponding compounds
of
the invention comprising Lys at the C-terminus, which may be cleaved from
other
5 compounds of the invention, including those with amino acid sequences SEQ
ID No: 4
to SEQ ID No: 15, and SEQ ID No: 28 to SEQ ID No: 34, respectively following
administration.
Nevertheless, compounds of the invention with amino acid sequences SEQ ID No:
16
10 to SEQ ID No: 27 and SEQ ID No: 35 to SEQ ID No: 41 are also compounds
of the
invention in their own right and may be made, formulated and administered to
patients
in exactly the same fashion as other compounds of the invention that are
described
herein and/or exemplified below.
15 For the avoidance of doubt, as used herein, Pro represents proline, Ala
represents
alanine, Ser represents serine, Tyr represents tyrosine, Hyp represents
hydroxyproline
(including 3-hydroxyproline (3Hyp) and 4-hydroxyproline (4Hyp)), diHyp
represents
dihydroxyproline (including 3,4-dihydroxyproline (3,4diHyp), 3,5-
dihydroxyproline
(3,5diHyp) and 4,5-dihydroxyproline (4,5diHyp)), Thr represents threonine, Lys
20 represents lysine, Ala represents alanine and DOPA represents 314-
dihydroxyphenylalanine. The optional 3,4-dihydrocinnamic acid residue that may
be
attached to W at the N-terminus is essentially a DOPA residue but without the -
NH2
group in the 2- or a-carbon position relative to the carboxylic acid that is
attached the
N-terminus (whether Ala, Ser or Lys).
Compounds of the invention, whether in the form of salts or otherwise, include
regioisomers within amino acids of the peptides (for example diHyp, Hyp and
Tyr
moieties), as well as mixtures of such regioisomers. For example, included
within the
definition of Tyr are, not only tyrosine (4-hydroxyphenylalanine), but also 2-
and 3-
30 hydroxyphenylalanine. Included within the definition of Hyp are 4-
hydroxyproline
(4Hyp), 3-hydroxyproline (3Hyp) and 5-hydroxyproline (5Hyp). It is more
preferred
that Hyp residues are 4-hydroxyproline. Similarly, included within the
definition of
diHyp are 3,4-dihydroxyproline (3,4diHyp), 3,5-dihydroxyproline (3,5diHyp) and
4,5-
dihydroxyproline (4,5diHyp). It is more preferred that diHyp residues are 3,4-
35 dihydroxyproline (3,4diHyp).
Also, in addition to the standard central carbon atom of the amino acids in
the
compounds of the invention (which are normally but not exclusively in the L-
7
CA 03150864 2022-3-10
RECTIFIED SHEET ( RULE 91 )
WO 2021/047648
PCT/CN2020/114828
configuration), certain amino acids in the sequence comprise further chiral
carbon
atoms. All such stereoisomers and mixtures (including racemic mixtures)
thereof are
induded within the scope of the invention. In respect, included within the
definition
of Hyp are trans-4-hydroxy-L-proline, cis-4-hydroxy-L-proline, trans-3-hydroxy-
L-
proline, cis-3-hydroxy-L-proline trans-5-hydroxy-L-proline and cis-5-hydroxy-L-
proline, however we prefer that the Hyp that is employed in compounds of the
invention
is 4-hydroxy-L-proline. Similarly, corresponding definitions may be applied to
diHyp,
in which the two hydroxy groups can also be cis or trans relative to each
other. In
any event, individual enantiomers of compounds of formula I that may form part
of a
compound of the invention are induded within the scope of the invention.
Compounds of the invention may be in the form of salts. Salts that may be
mentioned
indude pharmaceutically-acceptable and/or cosmetically-acceptable salts, such
as
pharmaceutically- and/or cosmetically-acceptable acid addition salts and base
addition
salts. Such salts may be formed by conventional means, for example by reaction
of
a compound of the invention with one or more equivalents of an appropriate
acid or
base, optionally in a solvent, or in a medium in which the salt is insoluble,
followed by
removal of said solvent, or said medium, using standard techniques (e.g. in
vacuo, by
freeze-drying or by filtration). Salts may also be prepared by exchanging a
counter-
ion of active ingredient in the form of a salt with another counter-ion, for
example
using a suitable ion exchange resin.
Preferred salts include, for example, acetate, hydrochloride, bisulfate,
maleate,
mesylate, tosylate, alkaline earth metal salts, such as calcium and magnesium,
or alkali
metal salts, such as sodium and potassium salts. Most preferably, compounds of
the
invention may be in the form of acetate salts.
Compounds of the invention may be prepared by way of conventional techniques,
for
example by way of standard amino acid coupling techniques, using standard
coupling
reagents and solvents, for example as described hereinafter. Compounds of the
invention may be synthesised from available starting materials using
appropriate
reagents and reaction conditions. In this respect, the skilled person may
refer to inter
alia"Comprehensive Organic Synthesis" by B. M. Trost and I. Fleming, Pergamon
Press,
1991. Further references that may be employed include "Heterocyclic Chemistry'
by
J. A. Joule, K. Mills and G. F. Smith, 3rd edition, published by Chapman &
Hall,
"Comprehensive Heterocyclic Chemistry it' by A. R. Katritzky, C. W. Rees and
E. F. V.
Scriven, Pergamon Press, 1996 and "Science of Synthesis", Volumes 9-17
(Hetarenes
and Related Ring Systems), Georg Thieme Verlag, 2006.
8
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Compounds of the invention may be isolated from their reaction mixtures and,
if
necessary, purified using conventional techniques as known to those skilled in
the
art. Thus, processes for preparation of compounds of the invention as
described
5 herein may include, as a final step, isolation and optionally
purification of the compound
of the invention.
It will be appreciated by those skilled in the art that, in the processes
described above
and hereinafter, the functional groups of intermediate compounds may need to
be
10 protected by protecting groups. The protection and deprotection of
functional groups
may take place before or after a reaction.
Protecting groups may be applied and removed in accordance with techniques
that are
well-known to those skilled in the art and as described hereinafter. For
example,
15 protected compounds/intermediates described herein may be converted
chemically to
unprotected compounds using standard deprotection techniques. The type of
chemistry involved will dictate the need, and type, of protecting groups as
well as the
sequence for accomplishing the synthesis. The use of protecting groups is
fully
described in µµProtective Groups in Organic Synthesis", 5th edition, T.W.
Greene et
20 P.G.M. Wutz, Wiley-Interscience (2014), the contents of which are
incorporated herein
by reference.
Compounds of the invention are useful because they possess pharmacological
activity.
Thus, the compounds of the invention are useful as human and animal medicine.
They
25 are therefore indicated as pharmaceuticals (and/or in veterinary science),
although
they may also be used as cosmetics and/or as part of a medical device.
Although compounds of the invention may possess pharmacological activity as
such,
certain pharmaceutically-acceptable (e.g. "protected") derivatives of
compounds of the
30 invention may exist or may be prepared which may not possess such
activity, but which
may be administered and thereafter be metabolised or chemically transformed to
form
compounds of the invention. Such
compounds (which may possess some
pharmacological activity, provided that such activity is appreciably lower
than that of
the active compounds to which they are metabolised/transformed) may therefore
be
35 described as 'prodrugs' of compounds of the invention.
As used herein, references to prodrugs will include compounds that form a
compound
of the invention, in an experimentally-detectable amount, within a
predetermined time,
9
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
following administration. All prodrugs of the compounds of the invention are
included
within the scope of the invention.
Compounds of the invention are particularly useful in the treatment of
inflammation.
The 'treatment of inflammation' includes the treatment of inflammation in any
organ
of the body (including soft tissue, joints, nerves, the vascular system,
internal organs,
especially mucosal surfaces, and particularly the skin), irrespective of the
cause, and
also includes all such inflammatory disorders or conditions, and/or disorders
or
conditions characterized by inflammation (e.g. as a symptom).
Inflammatory disorders and/or conditions may be (and are typically)
characterized by
activation of immune defence mechanisms, resulting in an effect that is more
harmful
than beneficial to the host. Such conditions are generally associated with
varying
degrees of tissue redness or hyperemia, swelling, edema, hyperthermia, pain
(including aching), exudation of body fluids, itching (pruritis), cell death
and tissue
destruction, cell proliferation, and/or loss of function.
Inflammatory conditions that may be mentioned include arteritis, diabetes
mellitus,
metabolic syndrome, rosacea, asthma and allergy, ankylosing spondylitis,
chronic
obstructive pulmonary disease, gouty arthritis, inflammatory bowel disease
(such as
Crohn's disease and ulcerative colitis), multiple sclerosis, osteoarthritis,
pancreatitis,
prostatitis, psoriatic arthritis, rheumatoid arthritis, tendinitis, bursitis,
Sjogren's
syndrome, systemic lupus erythematosus, uveitis, urticaria, vasculitis,
mastocytosis,
diabetic vascular complications, migraine, atherosclerosis and associated
cardiovascular disorders. A disease state characterised by inflammation that
may be
mentioned is chronic obstructive pulmonary disease (COPD). A further disease
state
characterised by inflammation that may be mentioned is inflammatory bowel
diseases
induding Crohn's disease and, especially, ulcerative colitis. Other disease
states
characterized by inflammation that may be mentioned are gynaecological
diseases,
such as cervicitis, vaginitis and colpitis. Diseases that affect the
gastrointestinal tract,
such as gastrohelcosis (e.g. gastritis, gastric ulcer, gastric cancer and
other stomach
mucosa diseases) as well as gastroesophageal reflux disease (GERD),
constipation,
and gastritis, inflammation associated with cancers and infections (e.g. viral
infections,
such as the common cold or influenza).
Inflammatory conditions that may be more especially mentioned include
inflammations
of the skin or mucosa (including the oral, nasal, ocular, vaginal, cervical
and/or
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
anorectal mucosae, more particularly the oral or nasal mucosae), such as
inflammation
resulting from infections (such as viral and/or bacterial infections), or
allergiqatopic
conditions (such as rhinitis (e.g. allergic rhinitis), pharyngitis,
periodontitis, gingivitis,
xerophthalmia, conjunctivitis (e.g. allergic conjunctivitis), dermatitis,
urticaria (hives)
5 and food allergy); and other inflammatory conditions, such as herpes,
drug eruptions,
polymorphous light eruptions, sunburn, early manifestations of skin cancers
(erythema-like skin lesions), pathological hair loss (including following skin
grafting),
chemo rash, psoriasis, erythema multiforme, folliculitis, eczema and external
otitis. A
disease state that may be mentioned is polymorphous light eruptions.
More particularly, compounds may be used to treat certain conditions
characterized by
inflammation, and/or with which inflammation is associated. Such conditions
may
indude wounds (including abrasions (scratches), incisions (including operative
incisions), lacerations, punctures, avulsions, bruising and scarring), and
burns
15 (including inflammation resulting from surgery following burns, such as
skin grafting)
and other conditions, such as hemorrhoids. Wounds may be acute or chronic,
and/or
may result from one or more inflammatory disorders as defined herein.
Wounds of the skin or mucosa may arise from internal or external physical
injury to
the membrane surface, or may be caused by (i.e. be a symptom of) an underlying
physiological disorder.
Physical (e.g. "open") wounds may be caused by sharp objects (cuts, incisions,
punctures) or blunt objects/mechanical forces (lacerations, abrasions,
avulsions),
25 physical blows (bruises), heat or chemicals (burns and blisters), UV
light (sunburn),
cold (chilblains or frostbite). Wounds may be superficial (damage only to the
epidermis and/or dermis) or may be full thickness wounds (damage below the
epidermis and/or dermis). In serious cases, subcutaneous and/or submucosal
tissues,
such as muscles, bones, joints, and even internal organs, may be damaged.
Compounds of the invention may be used to relieve the pain (including aching)
associated with inflammation and/or wounding. In particular, compounds of the
invention may be used to relieve procedural pain and/or non-procedural pain.
The
skilled person will understand that the term "procedural pain" (i.e. operation
pain)
refers to acute pain that is associated with medical investigations and
treatments
conducted for the purpose of healthcare. The term "non-procedural" refers to
general
pain that is associated with inflammation and/or wounding (e.g. pain
associated with
11
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
dental ulcers, burns and/or scars), and is not a consequence of a particular
medical
intervention.
Compounds of the invention may be used to treat not only the inflammation,
pain
5 (including aching) and/or pruritis (itching) associated with the wound
itself and the
healing process, but also they may be used to prevent the exudation of body
fluids
from wounds, the risk of infection, and also the prevention of physiological
reactions
that result from inflammation and/or wound healing processes, such as scarring
and
melanin pigmentation.
Scarring is a consequence of inflammation and/or wound healing and is a
general term
for the formation of fibrotic tissue that is a consequence of such
inflammation/healing.
Compounds of the invention may also be useful in the suppression of the
production
of melanin pigmentation, which may or may not result from inflammation and/or
wound healing. Compounds of the invention may also be useful in the
suppression of
disorders associated with melanin pigmentation, such as chloasma, freckles,
melanosis,
malar rash and other chromatosis, skin cancers with melanoma, and chromatosis
that
is caused by exposure to the sun or skin diseases like acne.
Wounds may also arise as a consequence of (e.g. inflammatory) diseases or
disorders.
Such wounds may include blistering and/or ulcers of the skin and mucosa. These
are
common conditions that are often long-lasting and difficult to treat. Skin
tissues can
often be damaged, removed, liquefied, infected and/or necrotic. Ulcers can
lead to
25 secondary consequences to health particularly if they become infected,
are hard to heal
and are costly to treat. They can also cause significant psychological stress
and
economic loss to patients, affecting both general well-being and quality of
life.
In the alternative, inflammatory skin conditions or diseases in which
compounds of the
30 invention find particular utility include psoriasis, acne, eczema and
dermatitis,
especially allergic/atopic dermatitis, as well as in the treatment of mucosal
inflammation as characterized by rhinitis, especially allergic rhinitis,
hemorrhoids,
chronic obstructive pulmonary disease and ulcerative colitis, for example.
35 Psoriasis is a chronic, inflammatory skin disease with a tendency to
recur (some
patients never heal during their entire life). Clinical manifestations of
psoriasis mainly
indude erythema and scales. It can occur over the whole body, but is more
commonly
observed on the scalp and limbs.
12
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Acne is a follicular (pilosebaceous unit) chronic, inflammatory skin disease,
the
occurrence of which is closely related to main factors like hypersteatosis,
blocked
pilosebaceous ducts (including closed and open comedones), bacterial infection
and
5 inflammatory reactions, that tends to occur during youth, characterized
by multiform
skin lesions on the face. The term acne thus includes regular acne and acne
rosacea
(i.e. copper nose).
Eczema is a skin inflammatory reaction with strong itching caused by a variety
of
10 internal and external factors. It has three phases, acute, sub-acute,
and chronic. In
the acute phase, there is a tendency for the production of exudates, while the
chronic
phase includes infiltration and hypertrophy. Skin lesions are often itchy and
recur
easily.
15 Dermatitis is a common skin disease characterized by coarseness,
redness, itching,
eczema, and dryness. Small lumps, refractory ulcers, and pigmented spots
caused by
dermatitis may, if not treated promptly, develop to basal cell carcinoma,
squamous cell
carcinoma, and malignant melanoma. Dermatitis may be caused by various
internal
and external infectious or non-infectious factors, including substances
(contact
20 dermatitis) or allergy (allergic/atopic dermatitis). Also included is
seborrheic dermatitis
(seborrheic eczema) and all forms of steroid-dependent dermatitis (including
light-
sensitive seborrheid, perioral dermatitis, rosacea-like dermatitis, steroid-
rosacea,
steroid-induced rosacea, iatrosacea, steroid dermatitis resembling rosacea,
topical
corticosteroid-induced rosacea-like dermatitis and, more particularly, facial
25 corticosteroid addictive dermatitis (FCAD) or facial corticosteroid-
dependent dermatitis
(FCDD), as characterized by flushing, erythema, telangiectasia, atrophy,
papules
and/or pustules in the facial area after long-term treatment with (including
uncontrolled use, abuse or misuse of) topical corticosteroids; see, for
example, Xiao et
al, J. Dermatol, 42, 697 (2015) and Lu eta!, Cl/n. Exp. Dermatol., 35, 618
(2009)).
Rhinitis is irritation and inflammation of the mucous membrane inside the
nose.
Common symptoms of rhinitis include a stuffy nose, runny nose, sneezing and
post-
nasal drip. The most common kind of rhinitis is allergic rhinitis, caused by
an allergen,
such as pollen, dust, mould, or flakes of skin from certain animals. It has
been
35 surprisingly found that patients with allergic rhinitis who were treated
compounds of
the invention experienced relief of eye itchiness, even when compounds of the
invention were administered nasally (i.e. to the nasal mucosa).
13
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Hemorrhoids are swellings caused by inflammation of the hemorrhoidal blood
vessels
found inside or around the rectum and the anus. Symptoms include bleeding
(i.e.
wounding) after the passage of a stool, prolapse of the hemorrhoid, mucus
discharge
and itchiness, soreness, redness and swelling in the area of the anus.
Hemorrhoids
are believed to be a consequence of an increase of pressure in the abdomen,
for
example, as a result of constipation or diarrhea.
Chronic obstructive pulmonary disease (COPD) is the name for a group of lung
conditions that cause breathing difficulties, including emphysema (damage to
the
alveoli) and chronic bronchitis (long-term inflammation of the airways). COPD
occurs
when the lungs become inflamed, damaged and narrowed. The damage to the lungs
is usually irreversible and results in an impairment of the flow of air into
and out of the
lungs. Symptoms of COPD include breathlessness, productive cough, frequent
chest
infections and persistent wheezing. The most common cause of the disease is
smoking, although other risk factors include high levels of air pollution and
occupational
exposure to dust, chemicals and fumes.
Compounds of the invention may have positive effects in mitigating erythema,
redness
and swelling, edema, blisters, and bullous pemphigoid caused by various
conditions
induding those mentioned generally and specifically herein, and may inhibit
exudation
of subcutaneous tissue fluid, and suppressing itching and pain caused by such
inflammatory conditions.
Other inflammatory conditions that may be mentioned include:
(a) Mucosal inflammation, such as oral mucositis, aphthous ulcers, otitis
media,
laryngitis, tracheitis, esophagitis, gastritis, enteritis and enterocolitis
(including
bacillary dysentery, chronic amoebic dysentery, schistosomiasis, nonspecific
ulcerative
colitis and regional enteritis), cervicitis and endocervidtis, endometritis,
inflammation
caused by inhalation injury and the like, as well as mucosal inflammation
associated
with cancers, and infections (e.g. viral infections, such as the common cold
or
influenza), that affect mucosal surfaces, such as those in the oral cavity,
the
nasopharynx, the ear, the throat, the trachea, the gastrointestinal tract, the
cervix,
etc.
(b) Orthopedic inflammation associated with, for example bone fractures,
pyogenic
infection of bones and joints, inflammation caused by rheumatic bone diseases,
as well
as pyogenic osteomyelitis (acute, chronic, localized, sclerotic, post-
traumatic),
14
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
pyogenic arthritis; bone tumors (osteonna, osteoid osteoma, chondronna), bone
cysts,
osteoclastoma, primary bone sarcoma (osteosarcoma, chondrosarcoma,
osteofibrosarcoma, Ewing's sarcoma, non-Hodgkin's lymphoma, myeloma,
chordoma),
metastatic bone tumors, tumor-like lesions of bone (bone cyst, aneurysmal bone
cyst,
5 eosinophilic granuloma, fibrous dysplasia); and rheumatic arthritis.
(c) Nerve inflammation, such as peripheral polyneuritis, facial neuritis,
peripheral
neuritis, subcutaneous neuritis, ulnar neuritis, intercostal neuritis, etc.
10 (d) Subcutaneous and submucosal soft tissue inflammation, such as
myositis,
ligamentitis, tendonitis, panniculitis, capsulitis, lymphadenitis,
bubonadentitis,
tonsillitis, synovitis, fasciitis, and soft tissue inflammation caused by
injuries, contusion
or laceration of muscles, ligaments, fascia, tendons, membrana synovialis,
fat, articular
capsules, and lymphoid tissue.
(e) Vascular inflammation, such as allergic leukocytoclastic vasculitis,
allergic
cutaneous vasculitis, polyarteritis nodosa, thrombotic vasculitis,
granulomatous
vasculitis, lymphocytic vasculitis, vasculitis with abnormalities in blood
composition,
and rheumatic vasculitis, as well as vascular inflammation associated with
vascular
20 cancers caused by allergic leukocytoclastic vasculitis, polyarteritis
nodosa, thrombotic
vasculitis, granulomatous vasculitis, lymphocytic vasculitis, vasculitis with
abnormalities in blood composition, and rheumatic vasculitis.
(f) Inflammation of the internal organs, such as the heart, stomach,
intestine, lung,
25 liver, spleen, kidney, pancreas, bladder, ovary, and prostate, including
but not limited
to pericarditis, myocarditis, endocarditis, pneumonia, hepatitis, splenitis,
nephritis
pancreatitis, cystitis, oophoritis, prostatitis and treatment of gastric
ulcer.
(g) Inflammation of the eye and surrounding area, such as conjunctivitis,
keratitis (e.g.
30 acute epithelial keratitis, nummular keratitis, interstitial keratitis,
disciform keratitis,
neurotrophic keratitis, mucous plaque keratitis, herpes simplex keratitis,
herpes zoster
keratitis, bacterial keratitis, fungal keratitis acanthamoebic keratitis,
onchocercal
keratitis, superficial punctate keratitis, ulcerative keratitis, exposure
keratitis
photokeratitis and contact lens acute red eye), optic neuritis, etc.
(h) Inflammation of the gums and the oral cavity, such as periodontitis,
gingivitis,
dental ulcers, etc.
CA 03150864 2022-3-10 RECTIFIED SHEET (
RULE 91 )
WO 2021/047648
PCT/CN2020/114828
(i) Inflammation associated with rheumatism, such as rheumatic vasculitis,
rheumatoid
arthritis, rheumatic bone diseases, ankylosing spondylitis, bursitis, Crohn's
disease,
gout, infectious arthritis, juvenile idiopathic arthritis, osteoarthritis,
osteoporosis,
polymyalgia rheumatica, polymyositis, psoriatic arthritis, scleroderma,
SjOgren's
5 syndrome, spondyloarthropathies, systemic lupus erythematosus,
tendinitis, etc.
Compounds of the invention may also be used in the treatment of certain
specific
diseases of the digestive system, such as GERD, which may be characterized by
an
acidic taste in the mouth, regurgitation, heartburn, pain with swallowing
and/or sore
10 throat, increased salivation (water brash), nausea, chest pain, and
coughing. GERD
may cause injury of the esophagus, including reflux esophagitis (i.e.
inflammation of
the esophageal epithelium which may cause ulceration at or around the junction
of the
stomach and esophagus), esophageal strictures (i.e. the persistent narrowing
of the
esophagus caused by reflux-induced inflammation), Barrett's esophagus (i.e.
15 intestinal metaplasia (i.e. changes of epithelial cells from squamous to
intestinal
columnar epithelium of the distal esophagus) and/or esophageal adenocarcinoma
(a
form of cancer).
Compounds of the invention may also be used in the treatment of certain
specific
20 diseases of the respiratory system, such as pulmonary cystic fibrosis,
usual interstitial
pneumonia, allergic pneumonia, asbestosis, emphysema, pulmonary heart disease,
pulmonary embolism, etc. A spedfic disease state that may be mentioned in
idiopathic pulmonary fibrosis (IPF).
25 IPF is a diffuse and fatal pulmonary interstitial disease with
pathological features
induding alveolar epithelial damage, massive proliferation of lung
fibroblasts,
excessive deposition of extracellular matrix, ultimately leading to
irreversible lung
tissue damage. In the latter stages of the disease, subjects with IPF
experience
respiratory failure and death. It has been found that compounds of the
invention may
30 find utility in the treatment of IPF and/or alleviation of the symptoms
associated with
the disease.
Compounds of the invention are particularly useful in the treatment of the
following
lung and/or fibrotic conditions (whether otherwise mentioned herein or not):
lung
35 fibrosis, renal fibrosis, liver fibrosis, silicosis, acute bronchitis,
chronic bronchitis,
tracheobronchitis, bronchial asthma, status asthmatics, bronchiectasis, upper
respiratory tract infections, including the common cold and influenza),
allergic airway
inflammation, bacterial pneumonia, viral pneumonia, mycoplasma pneumonia,
16
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
reckettsia, radiaton pneumonia, pneumococcal (including staphylococcal,
streptococcal
and gram-negative bacillus) pneumonia, pulmonary candidiasis (including
aspergillosis,
mucormycosis, histoplasmosis, actinomycosis and nocardiosis), pulmonary
mycosis,
cryptococcosis, lung abscesses, anaphylactic pneumonia (Leoffer's syndrome),
extrinsic allergic alveolitis, pulmonary eosinophia (eosinophilosis),
obstructive
pulmonary emphysema, pulmonary edema, pulmonary tuberculosis, respiratory
alkalosis (acidosis), acute lung injury, interstitial lung disease, empyema,
lung fibroma
and cor pulmonale.
Particular mucosal disorders and disease in which compounds of the invention
find
utility include anorectal diseases, such as diarrhea, hemorrhoids, abscesses,
fistula,
fissures, anal itching, anal sinusitis, warts and rectal prolapse;
inflammatory bowel
disease, including Crohn's disease and, particularly, ulcerative colitis;
gynaecological
diseases, such as cervicitis, vaginitis, pelvic pain and disorders; and dental
diseases,
such as paradentitis, for example.
Compounds of the invention may further possess an antioxidation effect, by
increasing
SOD (superoxide dismutase) production and reducing lipid oxidation. Compounds
of
the invention may therefore be considered have antioxidant properties.
Compounds of the invention may also possess antipyretic properties that allow
for the
treatment of a fever and/or alleviate the symptoms thereof; for example, by
reducing
a subject's body temperature, which results in a reduction of fever. Compounds
of
the invention and formulations including them may therefore be considered to
be
antipyretics.
According to a further aspect of the invention there is provided a method of
treatment
of inflammation, of an inflammatory disorder, and/or of a disorder/condition
characterised by inflammation (for example as a symptom), which method
comprises
the administration of a compound of the invention or a salt thereof to a
patient in need
of such treatment.
For the avoidance of doubt, in the context of the present invention, the terms
"treatment", "therapy" and "therapy method" include the therapeutic, or
palliative,
treatment of patients in need of, as well as the prophylactic treatment and/or
diagnosis
of patients which are susceptible to, inflammation and/or inflammatory
disorders.
17
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Compounds of the invention may further possess antiviral properties that may
allow
for the treatment of a viral infection per se, that is treatment of a viral
infection, or a
viral disease, by interfering with the replication of the virus within a host,
as opposed
to the treatment of any symptoms of any viral infection or disease, such as
pain and/or
5 inflammation. Such antiviral properties may also allow for the prevention
of the onset
of such an infection or disease, the protection of cells in a host from (e.g.
further) viral
infection, prevention or arrest of the spread of viral infection or disease
(within a single
host, or from one host to a new host), or for the prevention of reactivation
of a virus
after latency in a host.
According to a further aspect of the invention there is provided a method of
treatment
of a viral infection, which method comprises the administration of a compound
of the
invention or a salt thereof to a patient in need of such treatment.
15 Viral infections that may be mentioned include those caused by viruses
in the following
families: adenoviridae (e.g. adenovirus), papillomaviridae (e.g. human
papillomavirus), polyomaviridae (e.g. BK virus; JC virus), herpesviridae (e.g.
herpes
simplex, type 1; herpes simplex, type 2; varicella-zoster virus; Epstein-Barr
virus;
human cytomegalovirus; human herpes virus, type 8), poxviridae (e.g.
smallpox),
20 hepadnaviridae (e.g. hepatitis B virus), parvoviridae (e.g. parvovirus
B19), astroviridae
(e.g. human astrovirus), caliciviridae (e.g. norovirus; Norwalk virus),
picomaviridae
(e.g. coxsackievirus, hepatitis A virus; poliovirus; rhinovirus),
coronoviridae (e.g.
severe acute respiratory syndrome virus), flaviviridae (e.g. hepatitis C
virus; yellow
fever virus; dengue virus; West Nile virus; tick-borne encephalitis virus),
retroviridae
25 (e.g. human immunodeficiency virus; HIV), togaviridae (e.g. rubella virus),
arenaviridae (e.g. Lassa virus), bunyaviridae (e.g. hantavirus; Crimean-Congo
hemorrhagic fever virus; Hantaan virus), filoviridae (e.g. Ebola virus;
Marburg virus;
Ravn virus), orthomyxoviridae (e.g. influenza viruses, including influenza A
virus (e.g.
H1N1 and H3N2 viruses), influenza B virus or influenza C virus),
paramyxoviridae (e.g.
30 measles virus; mumps virus; parainfluenza virus, respiratory syncytial
virus),
rhabdoviridae (e.g. rabies virus), hepeviridae (e.g. hepatitis E virus),
reoviridae (e.g.
rotavirus; orbivirus; coltivirus; Banna virus), as well as viruses not
assigned to families,
such as hepatitis D virus.
35 Viruses that may be more specifically mentioned include herpes simplex,
type 1 and
herpes simplex, type 2 viruses, human papillomavirus, influenza virus and
parainfluenza virus.
18
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Compounds of the invention may further possess antibacterial and/or
bacteriostatic
properties that may allow for the treatment of a bacterial infection per se,
that is
treatment of a bacterial infection, or a bacterial disease, by interfering
with bacterial
growth or proliferation in a host, as opposed to the treatment of any symptoms
of any
5 bacterial infection or disease, such as pain and/or inflammation.
Compounds of the
invention may therefore be considered to be bacteriocides and/or, preferably,
bacteriostatic agents.
Such antibacterial properties may also allow for the prevention of the onset
of such an
10 infection or disease, the protection of cells in a host from (e.g.
further) bacterial
infection, prevention or arrest of the spread of bacterial infection or
disease (within a
single host, or from one host to a new host), or for the prevention of
reactivation of a
bacterium after latency in a host.
15 According to a further aspect of the invention there is provided a
method of treatment
of a bacterial infection, which method comprises the administration of a
compound of
the invention or a salt thereof to a patient in need of such treatment.
As disdosed herein, compounds of the invention may further possess anticancer
20 properties that may allow for the treatment of a cancer per se, that is
treatment of a
cancer by interfering with the cancer as opposed to the treatment of any
symptoms of
the cancer, such as pain and/or inflammation. Such anticancer properties may
also
indude the prevention of the onset of such a disease e.g. by treating
inflammation and
thereby preventing such onset.
According to another aspect of the invention, there is provided a method of
treatment
of cancer, which method comprises the administration of a compound of the
invention
or a salt thereof to a patient in need of such treatment.
30 Particular cancers that may be mentioned include oral cancer, a
nasopharynx cancer,
a middle ear cancer, a conjunctival cancer, a throat cancer, a tracheal
cancer, an
esophageal cancer, a gastric cancer, an intestinal cancer, a cervical cancer,
an
endometrial cancer, skin cancer and the like caused by oral mucositis,
rhinitis, otitis
media, conjunctivitis, pharyngitis, laryngitis, tracheitis, esophagitis,
gastritis,
35 enterocolitis, cervicitis, endometritis, erythema-like skin lesions and
the like. A
particular skin cancer that may be mentioned is basal cell carcinoma.
19
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
"Patients" include reptilian, avian and, preferably, mammalian (particularly
human)
patients_
In accordance with the invention, compounds of the invention are preferably
5 administered locally or systemically, for example orally, intravenously
or intraarterially
(including by intravascular and other perivascular devices/dosage forms (e.g.
stents)),
intramuscularly, cutaneously, subcutaneously, transmucosally (e.g.
sublingually or
buccally), rectally, intravaginally, intradermally, transdermally, nasally,
pulmonarily
(e.g. tracheally or bronchially), preferably topically, or by any other
parenteral route,
in the form of a pharmaceutical preparation comprising the compound(s) in
pharmaceutically acceptable dosage form(s).
Administration by inhalation (e.g. nasally) is particularly useful when the
condition to
be treated is rhinitis or inflammation resulting from viral infections of the
airways (e.g.
15 upper respiratory tract infections such as the common cold and
influenza).
Pulmonary administration is particularly useful when the condition to be
treated is
COPD or IPF. Topical forms of administration may be enhanced by creating a
spray
comprising active ingredients, e.g. by using a powder aerosol or by way of an
aqueous
20 mist using an appropriate atomisation technique or apparatus, such as a
nebulizer.
Anorectal administration is particularly useful when the condition to be
treated is
hemorrhoids or ulcerative colitis, using an appropriate delivery means, such
as a
solution of foam to be injected or a suppository.
Administration to the lower gastrointestinal tract may also be achieved by
parenteral,
and particularly by peroral, delivery, by means of standard delayed- or
extended-
release coating techniques known to those skilled in the art. In particular,
distinct
parts of the upper or lower intestine may be targeted. For example, colonic
30 administration can also be achieved by way of colon-targeted drug
delivery means that
are initially administered perorally or parenterally.
Compounds of the invention may in the alternative be administered by direct
systemic
parenteral administration. Such administration may be useful in methods of
treatment of an inflammatory and/or fibrotic disorder or condition of one or
more
internal organs of a patient.
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Internal organs that may be mentioned include the stomach, the intestines, the
pancreas, the liver, the spleen, the bladder, the vascular system, the
ovaries, the
prostate, preferably the heart and the kidneys and more preferably the lungs.
5 Fibrotic conditions of internal organs that may be mentioned indude acute
and/or
severe internal fibrotic conditions characterised by the excessive
accumulation of
fibrous connective tissue (as described above) in and around inflamed or
damaged
tissue. Formulations of the invention may thus be useful in the treatment or
prevention of fibrogenesis (as described above) and the morbidity and
mortality that
10 may be associated therewith. Thus, (e.g. acute and/or severe) fibrotic
conditions of
the internal organs that may be treated with formulations of the invention
include
fibrosis of the liver, the kidneys, the lungs, the cardiovascular system,
induding the
heart and the vascular system, the pancreas, the spleen, the central nervous
system
(nerve fibrosis), bone marrow fibrosis, the eyesõ the vagina, the cervix, etc.
Inflammatory conditions of internal organs include any condition that is, or
may
develop into a condition that is, severe (i.e. one that requires intensive
medical
treatment), and in which some sort of inflammatory component is apparent, as
may
be characterised by detectable inflammation, and further in which morbidity is
manifest
20 (or is expected) and/or is life-threatening.
Inflammatory conditions that may be mentioned include one or more acute
disorders
or conditions of internal organs (i.e. one or more conditions that require, or
may
develop into a condition that requires, immediate medical interventions) that
are
25 characterized by inflammation (e.g. as a symptom), such as acute
internal injuries, in
one or more internal organs (including any of the organs mentioned
hereinbefore). By
treating such acute inflammatory disorders, formulations of the invention may
prevent
or arrest the development of symptoms (acute or chronic) that are associated
with
such conditions, and also may arrest the progress of morbidity and/or
mortality that is
30 associated with such conditions.
Acute inflammatory conditions that may be mentioned thus include conditions
such as
peritonitis, pancreatitis, colitis, proctitis, gastritis, duodenitis,
pharyngitis, GERD,
parodontitis and stomatitis. Particular acute inflammatory conditions that may
be
35 mentioned include acute injury to one or more internal organs (including
any of those
mentioned hereinbefore), such as acute lung injury, inhalation injury (such as
burns),
acute respiratory distress syndrome (ARDS), severe acute respiratory syndrome
(SAPS), and multiple-organ inflammation, injury and/or failure.
21
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Such conditions may be caused by internal or external trauma (e.g. injury or a
burn),
or by an infection by e.g. viruses, bacteria or fungi.
5 For example, multiple-organ inflammation, injury and/or failure may
result from
extensive and/or traumatic external injuries, including traumatic and/or
extensive
external burns. Traumatic external burns will be understood to include second-
degree,
and more particularly third-degree burns and fourth-degree, burns. Extensive
external bums will be understood to include burns that affect at least about
10%, such
10 as at least about 15%, including at least about 20% of a patient's body
area. External
(and internal) burns may result from exposure to heat, chemicals and the like.
Acute inflammatory and/or fibrotic conditions may also result from sepsis or
septic
shock, which can be caused by viral, bacterial or fungal infection.
Furthermore, acute
15 lung injury, ARDS and, particularly, SARS may be caused by viruses, such as
coronaviruses, include the novel SARS coronavirus 2 (SARS-CoV-2).
Thus, in addition, one or more of the aforementioned (e.g. acute) inflammatory
conditions may (indeed in some cases will likely) result in some form of
internal tissue
20 damage and/or dysfunction of relevant internal tissues. Relevant tissues
thus indude
(e.g. mucosa!) tissues, such as the respiratory epithelium. Such tissue damage
may
also give rise to one or more of the fibrotic conditions mentioned
hereinbefore. For
example, the SARS disease caused by the novel coronavirus SARS-CoV-2
(coronavirus
disease 2019 or COVID-19) is known in many cases to result in fibrosis, which
arise
25 from one or more of a number of factors, including inflammation.
In this respect, compounds of the invention and salts thereof find particular
utility in
the treatment of relevant inflammatory and/or fibrotic conditions on the basis
that such
conditions are often characterized by one or more comorbidities. By conditions
that
30 are 'characterized by comorbidities', we include that the main condition
in question
results in (or from) one more further medical conditions, including (and
indeed
preferably) those mentioned hereinbefore, at the same time, which conditions
may
interact and/or overlap with each other in some way.
35 Thus, there are provided:
= methods of treatment of at least one inflammatory and/or fibrotic
disorder or
condition of one or more internal organs of a patient, which method comprises
direct systemic parenteral administration of a compound of the invention, or a
22
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
pharmaceutically-acceptable salt thereof, to a patient in need of such
treatment;
= a method of treatment of two or more inflammatory and/or fibrotic
disorders
or conditions of one or more internal organs of a patient, which method
5
comprises direct systemic parenteral administration
of a compound of the
invention, or a pharmaceutically-acceptable salt thereof, to a patient in need
of such treatment; and
= a method of reduction in the incidence of morbidity and/or mortality that
is or
may be associated with one or more inflammatory and/or fibrotic disorders or
10
conditions of one or more internal organs of a
patient, which method comprises
direct systemic parenteral administration of a compound of the invention, or a
pharmaceutically-acceptable salt thereof, to a patient in need of such
treatment.
15 When compounds of the invention/salts thereof are administered directly and
parenterally, they may be administered intravenously, intraarterially,
intravascularly,
perivascularly, intramuscularly, cutaneously, and/or subcutaneously, for
example by
way of direct injection, or by way of any other parenteral route, in the form
of a
compound of the invention or salt thereof in the form of a pharmaceutically-
acceptable
20 dosage form.
Pharmaceutically-acceptable formulations for use in such administration may
thus
comprise compounds of the invention in admixture with a pharmaceutically-
acceptable
adjuvant, diluent or carrier, which may be selected with due regard to the
intended
25
route of direct parenteral administration and
standard pharmaceutical practice. Such
pharmaceutically-acceptable carriers may be chemically inert to the active
compounds
and may have no detrimental side effects or toxicity under the conditions of
use. Such
pharmaceutically-acceptable carriers may also impart an immediate, or a
modified,
release of the active ingredient.
Formulations of the invention for injection may thus be in the form of an
aqueous
formulation such as an a suspension and/or, more preferably a solution (e.g.
an
(optionally) buffered aqueous formulation (e.g. solution), such as a
physiological
saline-containing formulation (e.g. solution), a phosphate-containing
formulation (e.g.
35
solution), an acetate-containing formulation (e.g.
solution) or a borate-containing
formulation (e.g. solution), or a freeze-dried powder that may be
reconstituted with a
vehicle, such as an aqueous vehicle prior to use (e.g. injection).
23
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Formulations of the invention may include other suitable excipients known to
those
skilled in the art, such as solvents (e.g. water), co-solvents, solubilizing
agents (e.g.
cyclodextrins), wetting agents, suspending agents, emulsifying agents,
thickening
agents, chelating agents, antioxidants, reducing agents, antimicrobial
preservatives,
5 bulking agents and/or protectants.
Formulations of the invention are preferably buffered by standard techniques
to
physiologically-acceptable pH values (e.g. pHs of between about 4.5 and about
9.5,
e.g. about 6 and about 9, such as between about 6.5 and about 8.5) using
buffers
and/or pH modifiers as described herein, and/or may further comprise tonicity-
modifying agents (such as sodium chloride).
The above notwithstanding, preferred modes of delivery of compounds of the
invention
include topically to the site of inflammation (e.g. the mucosa, including the
oral and/or
15 nasal mucosa, the lung, the anorectal area and/or the colon) or, more
preferably, the
skin) in an appropriate (for example pharmaceutically- and topically-
acceptable)
vehicle suitable for application to the skin and/or the appropriate mucosal
surface,
and/or a commercially-available formulation, but may also indude oral,
intravenous,
cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal, or pulmonary
20 delivery.
Administration by intradermal injection (e.g. intradermally) is particularly
useful for
administering the active ingredient, in the form of a solution or suspension
(e.g. a
dermal filler), into the dermis. This is particularly useful as a means of
administration
25 for melanin pigmentation therapy as described hereinbefore.
Compounds of the invention will generally be administered in the form of one
or more
for example pharmaceutical formulations in admixture with a (e.g.
pharmaceutically
acceptable) adjuvant, diluent or carrier, which may be selected with due
regard to the
30 intended route of administration (e.g. topical to the relevant mucosa
(including the
lung) or, preferably, the skin) and standard pharmaceutical or other (e.g.
cosmetic)
practice. Such pharmaceutically acceptable carriers may be chemically inert to
the
active compounds and may have no detrimental side effects or toxicity under
the
conditions of use. Such pharmaceutically acceptable carriers may also impart
an
35 immediate, or a modified, release of the active ingredient.
Suitable pharmaceutical formulations may be commercially available or
otherwise
prepared according to techniques that are described in the literature, for
example,
24
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Remington The Science and Practice of Pharmacy, 22nd edition, Pharmaceutical
Press
(2012) and Martindale ¨ The Complete Drug Reference, 38th Edition,
Pharmaceutical
Press (2014) and the documents referred to therein, the relevant disclosures
in all of
which documents are hereby incorporated by reference. Otherwise, the
preparation
5 of suitable formulations including compounds of the invention may be
achieved non-
inventively by the skilled person using routine techniques.
Compounds of the invention may be in the form of an aqueous formulation such
as an
emulsion, a suspension and/or a solution (e.g. an (optionally) buffered
aqueous
10 formulation (e.g. solution), such as a physiological saline-containing
formulation (e.g.
solution), a phosphate-containing formulation (e.g. solution), an acetate-
containing
formulation (e.g. solution) or a borate-containing formulation (e.g.
solution), or a
freeze-dried powder.
15 Active ingredient may further and/or in the alternative be combined with
appropriate
excipients to prepare:
= gel formulations (for which suitable gel matrix materials include
cellulose
derivatives, carbomer and alginates, gummi tragacanthae, gelatin, pectin,
carrageenan,
gellan gum, starch, Xanthan gum, cationic guar gum, agar, noncellulosic
20 polysaccharides, saccharides such as glucose, glycerin, propanediol,
vinyl polymers,
acrylic resins, polyvinyl alcohol, carboxyvinyl polymer and, particularly,
hyaluronic
acid);
= lotions (for which suitable matrix materials include cellulose
derivatives, glycerin,
noncellulosic polysaccharides, polyethylene glycols of different molecular
weights and
25 propanediol);
= pastes or ointments (for which suitable paste matrix materials include
glycerin,
vaseline, paraffin, polyethylene glycols of different molecular weights,
etc.);
= creams or foams (for which suitable excipients (e.g. foaming agents)
include
hydroxypropyl methyl cellulose, gelatin, polyethylene glycols of different
molecular
30 weights, sodium dodecyl sulfate, sodium fatty alcohol polyoxyethylene
ether sulfonate,
corn gluten powder and acrylamide);
= powder aerosols (for which suitable excipients include mannitol, glycine,
dextrin,
dextrose, sucrose, lactose, sorbitol and polysorbates, e.g. a dry powder
inhalant);
and/or
35 = liquid, for example, water (aerosol) sprays for oral use or for
inhalation (for which
suitable excipients include viscosity modifiers, such as hyaluronic acid,
sugars, such as
glucose and lactose, emulsifiers, buffering agents, alcohols, water,
preservatives,
sweeteners, flavours, etc.);
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
= injectable solutions or suspensions (which may be aqueous or otherwise
and for
which suitable excipients include solvents and co-solvents, solubilizing
agents, wetting
agents, suspending agents, emulsifying agents, thickening agents, chelating
agents,
antioxidants, reducing agents, antimicrobial preservatives, buffers and/or pH
modifiers,
5 bulking agents, protectants and tonicity-modifying agents). Particular
injectable
solutions or suspensions that may be mentioned include dermal fillers (i.e.
injectable
fillers or soft-tissue fillers.
Moisturizing agents, such as glycerol, glycerin, polyethylene glycol,
trehalose, glycerol,
10 petrolatum, paraffin oil, silicone oil, hyaluronic add and salts (e.g.
sodium and
potassium salts) thereof, octanoic/caprylic triglyceride, and the like; and/or
antioxidants, such as vitamins and glutathione; and/or pH modifiers, such as
adds,
bases and pH buffers, may also be included in such formulations, as
appropriate.
Furthermore, surfactants/emulsifiers, such as hexadecanol (cetyl alcohol),
fatty acids
15 (e.g. stearic acid), sodium dodecyl sulfate (sodium lauryl sulfate),
sorbitan esters (e.g.
sorbitan stearate, sorbitan oleate, etc.), monoacyl glycerides (such as
glyceryl
monostearate) polyethoxylated alcohols, polyvinyl alcohols, polyol esters,
polyoxyethylene alkyl ethers (e.g. polyoxyethylene sorbitan monooleate),
polyoxyethylene castor oil derivatives, ethoxylated fatty acid esters,
20 polyoxylglycerides, lauryl dimethyl amine oxide, bile salts (e.g. sodium
deoxycholate,
sodium cholate), phospholipids,
N,N-di methyldodecylamine-N -oxide,
hexadecyltrimethyl-ammonium bromide, poloxamers, lecithin, sterols (e.g.
cholesterol), sugar esters, polysorbates, and the like; preservatives, such as
phenoxyethanol, ethylhexyl glycerin, and the like; and thickeners, such as
25 acryloyldimethyltaurate/VP copolymer, may be included. In particular
stearic acid,
glyceryl monostearate, hexadecanol, sorbitan stearate, cetyl alcohol,
octanoic/capric
glyceride etc. may be included, particularly in cream formulations.
Compounds of the invention, and (e.g. pharmaceutical) formulations (e.g.
aqueous
30 solutions, gels, creams, ointments, lotions, foams, pastes and/or dry
powders as
described above) including them, may further be combined with an appropriate
matrix
material to prepare a dressing or a therapeutic patch for application on a
biological
surface, such as the skin or a mucosa! surface. Such formulations may thus be
employed to impregnate a matrix material, such as gauze, non-woven cloth or
silk
35 paper. The therapeutic patch may alternatively be, for example, a band-
aid, a facial
mask, an eye mask, a hand mask, a foot mask, etc.
26
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Vaseline may be employed for use in applying such dressings to wounds, but we
have
also found that ointments based on PEGs (e.g. PEG 400) may be combined with
matrix
materials to prepare dressings without the need to use vaseline.
5 Compounds of the invention may be administered for inhalation by way of
suspension,
a dry powder or a solution. Suitable inhalation devices include pressurized
metered-
dose inhalers (pMDIs,), which may be hand-or breath-actuated and employed with
or
without a standard spacer device), dry powder inhalers (DPIs), which may be
single-
dose, multi-dose, and power-assisted, and soft mist inhalers (SMIs) or
nebulizers, in
10 which aerosol drug in a fine mist is delivered with slower velocity than
a spray delivered
using, for example, a pMDI.
In pMDIs, compounds of the invention may be administered as a pressurized
suspension of micronized particles distributed in a propellant (e.g. HFA,
along with
15 excipients, such as mannitol, lactose, sorbitol, etc.), or as an
ethanolic solutions, to
deliver one or more metered dose of between about 20 and about 100 pL with
each
actuation. Actuation may be effected by hand (e.g. pressing) or by inhalation
(breath-
actuation), involving a flow-triggered system driven by a spring
20 In DP's, compounds of the invention may be administered in the form of
micronized
drug particles (of a size between about 1 and about 5 pm), either alone or
blended
with inactive excipient of larger particle size (e.g. mannitol), inside a
capsule, which
may be pre-loaded or manually loaded into the device. Inhalation from a DPI
may
de-aggregate the medication particles and disperse them within the airways.
In SMIs, compounds of the invention may be stored as a solution inside a
cartridge,
which is loaded into the device. A spring may release the dose into a
micropump,
such that the dose is released when button is pressed, releasing jet streams
of drug
solution.
Various nebulizers may also be used to administer compounds of the invention
in the
form of a fine mist of aerosolized solution. Nebulizers may include breath-
enhanced
jet nebulizer (in which, with the assistance of a compressor, an air stream
moves
through jet causing drug solution to be aerosolized); breath-actuated jet
nebulizers (in
35 which, after a patient inhales, with the assistance of a compressor, an
air stream moves
through tube causing drug solution to be aerosolized); ultrasonic nebulizers
(in which
piezoelectric crystals vibrate causing aerosolization by heating causing
nebulization);
vibrating mesh nebulizers (in which piezoelectric crystals vibrate a mesh
plate causing
27
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
aerosolization to give very fine droplets without a significant change in
temperature of
the solution during nebulization).
According to a further aspect of the invention there is provided a process for
the
preparation of a pharmaceutical composition/formulation, as defined herein,
which
process comprises bringing into association a compound of the invention, as
hereinbefore defined, with one or more pharmaceutically-acceptable excipient,
as
hereinbefore defined.
Compounds of the invention may also be combined in treatment with one or more
growth factors selected from platelet-type growth factors (including platelet-
derived
growth factors, PDGFs); osteosarcoma-derived growth factors (ODGF), epidermal
growth factors (EGFs), transforming growth factors (TGFa and TGFf3),
fibroblast growth
factors (oFGF, OFGF), insulin-like growth factors (IGF-I, IGF-II), nerve
growth factors
(NGF), interleukin-type growth factors (IL-1, IL-1, IL-3), erythropoietin
(EPO), and
colony stimulating factor (CSF).
According to a further aspect of the invention there is provided a (e.g.
pharmaceutical)
composition comprising a compound of the invention and one or more
pharmaceutically-acceptable excipient, such as an adjuvant, diluent or
carrier.
Preferred formulations are suitable for application locally to e.g. the mucosa
(including
the oral and/or nasal mucosa, the lung, the anorectal area and/or the colon)
or, more
preferably, the skin and therefore comprise a topically-acceptable adjuvant,
diluent or
carrier.
There is thus further provided pharmaceutical compositions comprising
compounds of
the invention that are suitable for, adapted for, and/or packaged and
presented for
topical administration (e.g. to the mucosa, including the oral and/or nasal
mucosa, the
lung, the anorectal area and/or the colon, or, preferably, to the skin), as
well as the
use of such a formulation in the treatment of a disorder including
inflammation, an
inflammatory disorder and/or a condition characterized by inflammation (e.g.
as a
symptom) by way of direct topical administration of that formulation (e.g. to
the
mucosa, including the oral and/or nasal mucosa, the lung, the anorectal area
and/or
the colon, or, preferably, to the skin).
In relation to this aspect of the invention, for the avoidance of doubt,
topical
formulations comprising compounds of the invention may be used in any and all
conditions described herein, including treatments of inflammation, in the
treatment of
28
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
any and all inflammatory disorder(s), and/or in the treatment of any and all
condition(s)
characterized by inflammation, as hereinbefore mentioned, defined or
described.
Similarly, topical formulations comprising compounds of the invention that may
be
mentioned include any and all of those mentioned, defined or described herein.
Any
and all of the relevant disclosures herein are hereby incorporated by
reference in
conjunction with this aspect of the invention.
Topical (e.g. liquid- or (e.g. aqueous) solution-based) formulations
comprising
compounds of the invention may be particularly useful in wound recovery, and
may
alleviate pain (including aching) and, particularly, pruritis/itching that is
associated
with the wound itself and the wound healing process. Such topical formulations
comprising compounds of the invention may be particularly useful in the
prevention
and/or suppression of the exudation of body fluids from wounds, particularly
during
the acute inflammation stage, for example during the first 48 hours, after a
burn or
wound has been inflicted. This prevents the risk of infection, and other
physiological
reactions. Such topical formulations comprising compounds of the invention may
also
be particularly useful in the prevention and/or suppression of scarring and
melanin
pigmentation (vide supra), whether associated with wounds or otherwise.
Administration of active ingredients may be continuous or intermittent. The
mode of
administration may also be determined by the timing and frequency of
administration,
but is also dependent, in the case of the therapeutic treatment of
inflammation, on the
severity of the condition.
Depending on the disorder, and the patient, to be treated, as well as the
route of
administration, compounds of the invention may be administered at varying
therapeutically effective doses to a patient in need thereof.
Similarly, the amount of active ingredient in a formulation will depend on the
severity
of the condition, and on the patient, to be treated, but may be determined by
the
skilled person.
In any event, the medical practitioner, or other skilled person, will be able
to determine
routinely the actual dosage, which will be most suitable for an individual
patient,
depending on the severity of the condition and route of administration. The
dosages
mentioned herein are exemplary of the average case; there can, of course, be
individual instances where higher or lower dosage ranges are merited, and such
are
within the scope of this invention.
29
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Doses may be administered between once and four (e.g. three) times daily.
Appropriate concentrations of compounds of the invention in an aqueous
solution
product may be about 0.01 (e.g. about 0.1) to about 15.0 mg/mL, in all cases
calculated as the free (non-salt) compound.
Appropriate topical doses of compounds of the invention are in the range of
about 0.05
to about 50 pg/cm2 of treated area, such as about 0.1 (e.g. about 0.5) to
about 20
pg/cm2 of treated area, including about 1 to about 10 pg/cm2) of treated area,
such as
about 5 pg/cm2 of treated area, in all cases calculated as the free (non-salt)
compound.
Appropriate doses of compounds of the invention for nasal administration (e.g.
by
inhalation) are in the range of about 0.01 pg to about 2000 mg, for example
between
about 0.1 pg to about 500 mg, or between 1 pg to about 100 mg. Particular
doses
for nasal administration that may be mentioned include between about 10 pg to
about
1 mg, particularly a dose of about 0.1 mg (i.e. about 100 pg). Nasal
administration
of about 0.1 mg per day of compounds of the invention has been found to be
particularly effective in the treatment of conditions associated with
inflammation of the
nasal passages and mucosae, such as rhinitis (e.g. allergic rhinitis).
Appropriate doses of compounds of the invention for pulmonary administration
(e.g.
by inhalation) are in the range of about 0.01 pg to about 2000 mg, for example
between about 0.1 pg to about 500 mg, or between 1 pg to about 100 mg.
Particular
doses for pulmonary administration that may be mentioned include between about
10
pg to about 10 mg, particularly a dose of about 0.6 mg (i.e. 60 pg) to 6 mg
(e.g. for
use in treating COPD or IPF).
We prefer that p1-1 values of formulations comprising compounds of the
invention are
in the range of about 1.0 to about 9.0 (for example about 3.0 to about 8.0).
In any event, the dose administered to a mammal, particularly a human, in the
context
of the present invention should be sufficient to effect a therapeutic response
in the
mammal over a reasonable timeframe (as described hereinbefore). One skilled in
the
art will recognize that the selection of the exact dose and composition and
the most
appropriate delivery regimen will also be influenced by inter alia the
pharmacological
properties of the formulation, the nature and severity of the condition being
treated,
and the physical condition and mental acuity of the recipient, as well as the
age,
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
condition, body weight, sex and response of the patient to be treated, and the
stage/severity of the disease, as well as genetic differences between
patients.
In the uses and methods described herein, compounds of the invention may also
be
combined with one or more active ingredients that are useful in the treatment
of
inflammation and/or inflammatory disorders (other anti-inflammatory agents).
Such
patients may thus also (and/or already) be receiving therapy based upon
administration of one or more of such other active ingredients, by which we
mean
receiving a prescribed dose of one or more of those active ingredients
mentioned herein,
prior to, in addition to, and/or following, treatment with a compound of the
invention.
Such anti-inflammatory agents that may be used in combination with compounds
of
the invention in the treatment of inflammation include therapeutic agents that
are
useful in the treatment of inflammation and/or of diseases characterized by
inflammation as one of its symptoms. Depending on the condition to be treated,
such
anti-inflammatory agents may include NSAIDs (e.g. aspirin), leukotriene
receptor
antagonists (e.g. montelukast), corticosteroids, analgesics and certain
enzymes, such
as trypsin, for example as described hereinafter. Compounds of the invention
may
also be combined with leukotriene 64 (L1134).
In this context, compounds of the invention may also be combined for use in
the
treatment of inflammation with one or more mussel adhesive proteins (MAPs),
which
indudes any adhesive protein that may be derived from mussel species, such as
Mytilus
edulis (blue mussel), including full length proteins, including all sub-types,
that are or
may be derived from mussels, such as the collagens pre-COL-P, pre-COL-D and
pre-
COL-NG, the mussel feet matrix proteins PTMP and DTMP, and, more preferably,
mfps
or mefps, such as mefp-2, mefp-3, mefp-4, mefp-5, mefp-6 and especially mefp-
1,
and includes mixtures or combinations of any of these proteins, such as mefps.
Naturally-occurring MAPs may be prepared, for example by mixed adsorption
chromatography (see Chinese Patent No. ZL200710179491.0), by carboxymethyl ion
exchange chromatography (see Chinese Patent No. 7L200710179492.5), and/or by
salting out and dialysis (Chinese Patent No. ZL200910087567.6). Commercial
sources of MAPs include USUN Bio Co. (China; sold as MAP Medical Device ), BD
Siosciences (USA), Kollodis (South Korea) and Biopolymer (Sweden). MAPs may
alternatively be produced using known recombinant DNA methods.
Derivatives (e.g. pharmaceutically-acceptable derivatives) of MAPs may also be
combined with compounds of the invention and include compounds with, for
example,
31
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
molecular weights in the range of about 500 Da to about 2,000 Da (e.g. about
1,500,
such as about 1,200, including about 800 Da). Such derivatives may also
include
other compounds that comprise amino acid sequences that are the same as, or
are
(e.g. minor) variants (as hereinbefore defined) of, sequences that have been
identified
in naturally-occurring MAPs, and which may be synthesized by chemical and/or
biological processes (e.g. chemical modifications of naturally-occurring MAPs,
or direct
synthesis).
For example, as discussed hereinbefore, the isolated decapeptide compounds of
the
sequences:
Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (mefp-1 decapeptide, SEQ ID No: 1);
and
Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 2)
are pharmaceutically-acceptable low molecular weight derivatives of MAP that
may be
combined with a compound of the invention.
Other preferred agents that may be combined with compounds of the invention
include
LTB4 (to treat wounds and burns), NSAIDS (e.g. aspirin) or montelukast (to
treat
inflammation generally) and trypsin (to treat inflammation of the mucosa
associated
with e.g. viral infections).
Compounds of the invention may also be combined with other therapeutic agents
which,
when administered, are known to give rise to inflammation as a side-effect.
When compounds of the invention may be "combined" with other therapeutic
agents
in this way, the active ingredients may be administered together in the same
formulation, or administered separately (simultaneously or sequentially) in
different
formulations.
Such combination products provide for the administration of compounds of the
invention in conjunction with the other therapeutic agent, and may thus be
presented
either as separate formulations, wherein at least one of those formulations
comprises
a compound of the invention, and at least one comprises the other therapeutic
agent,
or may be presented (i.e. formulated) as a combined preparation (i.e.
presented as a
single formulation including a compound of the invention and the other
therapeutic
agent).
Thus, there is further provided:
32
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
(1) a pharmaceutical formulation including a compound of the invention;
another
anti-inflammatory agent, or agent known to give rise to inflammation as a side-
effect;
and a pharmaceutically-acceptable excipient (e.g. adjuvant, diluent or
carrier), which
formulation is hereinafter referred to as a "combined preparation"; and
(2) a kit of parts comprising components:
(A) a pharmaceutical formulation including a compound of the invention in
admixture
with a pharmaceutically-acceptable adjuvant, diluent or carrier; and
(B) a pharmaceutical formulation including another anti-inflammatory agent, or
agent
known to give rise to inflammation as a side-effect, in admixture with a
pharmaceutically-acceptable adjuvant, diluent or carrier,
which components (A) and (B) are each provided in a form that is suitable for
administration in conjunction with the other.
In a further aspect of the invention, there is provided a process for the
preparation of
a combined preparation as hereinbefore defined, which process comprises
bringing into
association a compound of the invention, the other antiinflammatory agent, or
agent
known to give rise to inflammation as a side-effect, and at least one (e.g.
pharmaceutically-acceptable) excipient.
In a further aspect of the invention, there is provided a process for the
preparation of
a kit-of-parts as hereinbefore defined, which process comprises bringing into
association components (A) and (B). As used herein, references to bringing
into
association will mean that the two components are rendered suitable for
administration
in conjunction with each other.
Thus, in relation to the process for the preparation of a kit-of-parts as
hereinbefore
defined, by bringing the two components "into association with" each other, we
include
that the two components of the kit-of-parts may be:
(i) provided as separate formulations (i.e. independently of one another),
which
are subsequently brought together for use in conjunction with each other in
combination therapy; or
(ii) packaged and presented together as separate
components of a "combination
pack" for use in conjunction with each other in combination therapy.
Thus, there is further provided a kit of parts comprising:
(I) one of components (A) and (B) as defined herein; together with
33
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
(H) instructions to use that component in conjunction with the other of the
two
components.
The kits of parts described herein may comprise more than one formulation
including
5 an appropriate quantity/dose of a compound of the invention, and/or more
than one
formulation including an appropriate quantity/dose of another anti-
inflammatory agent,
in order to provide for repeat dosing. If more than one formulation
(comprising either
active compound) is present, such formulations may be the same, or may be
different
in terms of the dose of either compound, chemical composition(s) and/or
physical
10 form(s).
With respect to the kits of parts as described herein, by "administration in
conjunction
with", we include that respective formulations comprising a compound of the
invention
and other anti-inflammatory agent are administered, sequentially, separately
and/or
15 simultaneously, over the course of treatment of the relevant condition.
Thus, in respect of the combination product according to the invention, the
term
"administration in conjunction with" includes that the two components of the
combination product (compound of the invention and other anti-inflammatory
agent)
20 are administered (optionally repeatedly), either together, or
sufficiently closely in time,
to enable a beneficial effect for the patient, that is greater, over the
course of the
treatment of the relevant condition, than if either a formulation comprising
compound
of the invention, or a formulation comprising the other agent, are
administered
(optionally repeatedly) alone, in the absence of the other component, over the
same
25 course of treatment. Determination of whether a combination provides a
greater
beneficial effect in respect of, and over the course of treatment of, a
particular
condition will depend upon the condition to be treated or prevented, but may
be
achieved routinely by the skilled person.
30 Further, in the context of a kit of parts according to the invention,
the term "in
conjunction with" includes that one or other of the two formulations may be
administered (optionally repeatedly) prior to, after, and/or at the same time
as,
administration of the other component. When used in this context, the terms
"administered simultaneously" and "administered at the same time as" include
that
35 individual doses of the relevant compound of the invention and other
anti-inflammatory
agent are administered within 48 hours (e.g. 24 hours) of each other.
34
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
In a further aspect of the invention, there is provided a process for the
preparation of
a combined preparation as hereinbefore defined, which process comprises
bringing into
association a compound of the invention or a salt thereof, as hereinbefore
defined, the
other anti-inflammatory agent, or agent known to give rise to inflammation as
a side-
5 effect, and at least one pharmaceutically-acceptable excipient.
Certain compounds of invention may in addition to, and/or instead of,
possessing the
aforementioned biological activity, possess adhesive properties.
10 Such compounds of the invention may adhere to a number of substrates
including
inorganic substrates, such as glass, metal and the like, as well as organic
substrates,
such as biological tissue.
In respect, such compounds of the invention may also be used as wound surface
repair
15 products, wound surface protecting products, medical biological adhesive
products,
medical coating products, industrial coating products (e.g. in corrosion
prevention in
ships, electronic apparatuses, pipelines and the like), biochemical reagents,
medical
products, sterilization products, culture vessels for cell culture and the
like.
20 Such compounds of the invention may form a film over various skin and
mucous wound
surfaces such as bums, scalds, ulcers, chilblains and bedsores to aid in
recovery. Such
compounds of the invention may also be used in surgery, e.g. in the closure of
surgical
incisions, adhesion of fractured bones, adhesion of mucous membranes, coatings
of
human body implants such as artificial bones, cartilage brackets, periostea,
artificial
25 joints, dental implants, plugging stents, spinal fusion devices, spinal
spacers and organ
patches.
According to a further aspect of the invention, there is provided a compound
of the
invention or a salt thereof as an adhesive or a film-forming material.
Wherever the word "about" is employed herein, for example in the context of
amounts,
such as concentrations and/or doses of active ingredients, molecular weights
or pHs,
it will be appreciated that such variables are approximate and as such may
vary by
10%, for example 5% and preferably 2% (e.g. 1%) from the numbers
specified
35 herein. In this respect, the term 'about 10%" means e.g. 10% about the
number
10, i.e. between 9% and 11%.
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Compounds of the invention have the advantage that they may be used in variety
of
conditions characterised by inflammation, whether that condition is an organic
inflammatory disease per se or is associated with, or is characterised by,
inflammation
(e.g. a wound, a bum or a viral infection).
Compounds of the invention may also have the advantage that they demonstrate
improved resistance to in vivo metabolism compared to compounds described in
the
prior art, including those defined by SEQ ID: No. 1 and/or SEQ ID: No. 2.
Compounds
of the invention may demonstrate improved resistance to metabolism by
chymotrypsin
(a digestive enzyme that breaks down proteins) and/or elastase (an enzyme that
breaks down elastin which, together with collagen, determines the mechanical
properties of connective tissue.
The compounds, uses and methods described herein may also have the advantage
that, in the treatment of the conditions mentioned hereinbefore, they may be
more
convenient for the physician and/or patient than, be more efficacious than, be
less
toxic than, have a broader range of activity than, be more potent than,
produce fewer
side effects than, or that it/they may have other useful pharmacological
properties
over, similar compounds or methods (treatments) known in the prior art,
whether for
use in the treatment of inflammation, inflammatory disorders, or disorders
characterised by inflammation as a symptom (including wounds), or otherwise.
The invention is illustrated by the following examples, in which, Figure 1
shows Evans
blue content in rectal and anal tissue indicating vascular permeability of
test
compounds.
Examples
Example 1
Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 15)
Fmoc-Lys-Boc-Wang resin (9.15 g, G1S180322-41301, GL Biochem, Shanghai, China)
was loaded into a glass reaction column.
Methylene chloride (DCM, 200 mL; Shandong Jinling Chemical Industry Co Ltd,
Shandong, China) was added to the column and allowed to soak the resin for
about
half an hour. The DCM was then removed by vacuum filtration.
36
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
The resin was washed 3 times with N,N-dimethylformamide (DMF, 200 mL; Shandong
Shitaifeng Fertilizer Industry Co Ltd, Shandong, China).
A 20% piperidine solution in DMF (200 mL) and was added as deprotection
solution
5 and reacted for 20 minutes. The solution was then removed by vacuum
filtration and
the column was washed with DMF six times. Fmoc-4-Hyp(tBu)-OH (GLS 21303; GL
Biochem, Shanghai, China) and
2-(1H-benzotriazole-1-y1)-111,3,3-
tetramethylaminium tetrafluoroborate (TBTU, 2.89 g; GLS 170805-00705, CI..
Biochem,
Shanghai, China) were added to the resin. DMF (150 mL) was added to the
reaction
column, followed by N,N-dilsopropylethylamine (DIPEA, 2.33 g; Suzhou Highfine
Biotech Co. Ltd, Jiangsu, China). A colour reaction was detected in the resin
after 30
minutes, indicating the reaction was complete. The solvent was removed by
vacuum
filtration.
The above coupling steps were repeated to couple the remaining amino acids in
the
same amounts (by mols): Fmoc-Tyr(tBu)-0H, Fmoc-Thr(tBu)-0H, Fmoc-4-Hyp(tBu)-
OH, Fmoc-Tyr(tBu)-0H, Fmoc-Ser(tBu)-0H, Fmoc-Pro-OH, Fmoc-Lys(Boc)-OH and
Fmoc-Ala-OH.
20 91.5 mL (i.e. 10 mL per gram of resin) of lysate, which comprised of 95%
trifiuoroacetic
acid (TFA), 2.5% water and 2.5% triisopropylsilane (us), was added to immerse
the
resin-bounded peptide compound. The side chains were also deprotected during
cleavage. After cleavage the solid support was removed by filtration and the
filtrate
is concentrated under reduced pressure. The cleaved peptide was precipitated
with
25 diethyl ether and lyophilized to yield crude title compound.
1 mg of crude product was dissolved in 1 mL of an acetonitrile and water
mixture (1:3)
and detected using a P3000A HPLC pump and LC3000 semi-preparation equipment
(preparation column model: GS-120-10-C18-AP 30 mm; Beijing Chuangxintongheng
30 Science & Technology Co., Ltd., Beijing,China). The appropriate gradient
for elution
was calculated and the target peak was detected at 11.035 with LCMS (analysis
column
model: GS-120-5-C18-BIO, 4.6*250 mm; detection: UV at 220 nm; solvent A: 0.1%
TFA in MeCN, solvent A: 0.1% TFA in water; flow rate 1.0 mL/min.; volume: 10
pL).
35 The crude compound was desalted using an anion exchange resin, analysed
and freeze-
dried. Purified peptide was obtained after purification.
37
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
The synthesis described above was repeated, with the exception that, after
Fmoc-Ala-
OH was coupled to the resin, a deprotection step was carried out to remove the
Fmoc
group, and the resin was washed 3 times with DMF (200 mL).
5 A 20% piperidine solution in DMF (200 mL) was added as a deprotection
solution and
reacted for 20 minutes. Then, the resin was washed three times each with the
following
solvents, DMF (200 mL), DCM (200 mL) and methanol (200 mL; Xilong Scientific
Co.,
Ltd., Guangdong, China). The resin was dried under vacuum for about 2 hours.
10 85.0 mL (i.e. 10 mL per gram of the dried resin) of lysate was added to
immerse the
resin-bounded peptide-containing compound. After cleavage for about 2 hours
the
solid support was removed by filtration and the filtrate was collected under
reduced
pressure. The filtrate was precipitated with 850 mL (i.e. 10 mL per ml of the
filtrate)
of diethyl ether (Xilong Scientific Co., Ltd., Guangdong, China) and the
sediment was
15 collected by filtration. The sediment was dried by vacuum for about 2
hours, yielding
3.66g of crude title compound.
The crude product was firstly analyzed as a 1 mg/mL sample in pure water and
detected using a Shimadzu LCMS-8050 system. The analysis column was an
Angilent
20 ZORBAX Eclipse SB-C18 (4.6 x 250 mm, 5 pm column; detection: UV at 220 nm;
solvent A: 0.1% TEA in MeCN, solvent B: 0.1% TEA in water, with a linear
gradient
from 5%-90% solvent A concentration in 50 minutes; flow rate 1.0 mL/min;
sample
volume: 10 pL).
25 The target peak was eluted at 9.537 minutes and had the expected
molecular weight,
with a purity of 77.256%.
MS: m/z 1183.1
30 3.6 g of crude product was then dissolved in 40 mL of pure water and
purified using
LC3000 semi-preparation equipment. The preparation column model was a Dubhe-
C18 model (Hanbon Sci. & Tech. Co., Ltd., Jiangsu, China) (50*250 mm column;
detection: UV at 220 nm). The appropriate gradient for elution was calculated
from
LCMS detection step (Solvent A: 0.1% TEA in MeCN, solvent B: 0.1% TEA in
water,
35 with a linear gradient from 5%-20% solvent A concentration in 30
minutes; flow rate
60.0 ml/mm;). Fractions were collected and analyzed using a Shimadzu LC-20
HPLC
system (column as above, except with a linear gradient from 5%-30% solvent A
concentration in 25 minutes).
38
CA 03150864 2022-3-10
W02021/047648
PCT/CN2020/114828
Fractions with a purity of 98% were then mixed together for an anion exchange
step.
This was achieved using a LC3000 semi-preparation equipment (preparation
column
model: Dubhe-C18 model (as above). The fractions were diluted once with pure
water
5 and loaded to the column directly, after that the column was washed with
0.37% of
ammonium acetate in pure water for about 20 minutes at the flow rate of 60
nnL/min,
then eluted with the following gradient (Solvent A: 0.1% HAc in MeCN, solvent
B: 0.1%
HAc in water, with a linear gradient from 5%/v20% solvent A concentration in
30
minutes; flow rate 60.0 mL/min). Fractions were collected and analyzed using
Shimadzu LC-20 HPLC system (column and conditions as above). Fractions with a
purity of 98% were mixed and freeze-dried to give 2.03 g of the purified title
compound.
Example 2
Croton Oil-Induced Anal Swelling Model in Rats
A gel comprising 0.5 g of the peptide Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys
(SEQ
ID No: 15; see Example 1 above) was made, which also consisted of the
following
components: methyl cellulose (2.2 g; Shandong Guangda Technology Development
Co., Ltd., ShanDong, China), glycerin (11 g) and propanediol 11 g (both
Sinopharm
20 Chemical Reagent Co. Ltd.), and purified water (75.3 g).
The methyl cellulose and water were mixed together and stirred until to a
homogeneous colloidal suspension was formed. Then, the peptide powder,
glycerin
and propanediol were added to the methyl cellulose/water mixture, and the
resultant
25 mixture quickly stirred for 5 minutes to obtain the finished product.
6-8 weeks old SD rats with average body weights of between 180 and 220 g were
supplied by Changzhou Cvens Experimental Animal Co. Ltd (Changzhou, Jiangsu
Province, China), half male and half female. Prior to any experiments being
conducted,
30 rats were housed under standardized conditions (at a constant
temperature or 22
2 C, with alternating 12-hour periods of light and darkness) and were fed on a
standard
rat diet with water, for about a week.
32 rats were randomly divided into 4 groups with 8 rats in each group.
Rats were anesthetized by isoflurane (China Pharmaceutical Group Chemical
Reagents
Co., Ltd) inhalation. A 75% alcohol cotton ball was used to disinfect the skin
around
the anus. 0.16 mL of croton oil mixture (one part distilled water, four parts
of pyridine
39
CA 03150864 2022-3-10 REC11FED SHEET (
RULE 91)
WO 2021/047648
PCT/CN2020/114828
(Nanjing Chemical Reagent Co., Ltd), five parts ether (China Pharmaceutical
Group
Chemical Reagents Co., Ltd) and ten parts 6% croton oil (Shanghai Yuanye
Biotechnology Co., Ltd) was dripped slowly onto the cotton swab, and inserted
into the
rat anus for 0.5 cm.
The rat was lifted the rat to keep the head upwards (maintaining for 10
seconds), then
the cotton swab was withdrawn and the croton oil mixture evenly applied to the
surrounding skin. The blank control group was given the same volume of olive
oil.
One hour alter modeling, rats in each group were treated as follows:
= control group - given normal saline ('Control'),
= model' group - treated with a blank gel with no active ingredients
('Model'),
= positive control - MaYinglong hemorrhoids ointment (MaYinglong
Pharmaceutical Group Co., Ltd.; tMayinglong')
= Peptide Gel (as above; 'Peptide')
200 pL of test substances were drawn with 1 mL syringe (with the needle
removed).
The syringe was inserted into the anal canal and about 160 mL of the
respective test
substances were pushed to about 1.5 cm in depth. The remaining drug was
applied to
the surrounding skin near the anus. The skin around the anus was held tightly
for
about 1 minute to prevent drug discharge.
In the morning of the fourth day, 1% Evans blue (ER) was injected into the
tail vein
minutes after drug administration (200 p1./100 g). The rats were the
sacrificed by
25 cervical dislocation after another 30 minutes.
The rats were place in the supine position on an anatomical plate and their
abdomens
were opened. The rectoanal tissues (15 mm in length) were isolated and weighed
and
the ER dye present in the tissue was extracted using 1 mL of formamide.
All samples were transferred to a 55 C water bath or a heat block. Incubation
for 24
hours extracted ER from the tissue. The formamide/EB mixture was centrifuged
to
pelletize any remaining tissue fragments. Absorbance was measured at 610 nm,
using
500 pL of formamide as a blank.
The content of ER in rectal and anal tissues was calculate using amount (in
ng) of ES
extravasated per mg of tissue to evaluate vascular permeability. The results
are
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
shown in Figure 1 and show that the test peptide may reduce inflammatory
swelling
caused by croton oil application.
Example 3
5 Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 14)
The title compound was prepared using essentially the same process as the
latter one
described in Example 1 above, except that Fmoc-DOPA(Acetonide)-OH was used
instead of Fmoc-Tyr(tBu)-OH in the relevant amino acid coupling step to yield
3.73 g
10 of crude title compound.
Analysis showed a target peak that was eluted at 9.297 minutes with the
expected
molecular weight (MS: m/z 1199.1). The purity was 74.493%.
15 3.7 g of the crude product was then purified as described in Example 1
above to give
2.01 g of pure title compound after freeze-drying.
Examole 4
3.4-Dihydroxyhydrocinnamic acid-Ala-Lvs-Pro-Ser-Tvr-Hvo-Thr-Tyr-Hyo-Lvs (SE0
ID
20 No: 29)
The title compound was prepared using essentially the same process as the
latter one
described in Example 1 above, except that a final coupling with 3,4-
dihydroxyhydrocinnamic acid was performed to yield 4.05 g of crude title
compound.
Analysis showed a target peak that was eluted at 9.716 minutes with the
expected
molecular weight (MS: miz 1347.1). The purity was 79.183%.
4.0 g of the crude product was then purified as described in Example 1 above
to give
30 2.67 g of pure title compound after freeze-drying.
Example 5
Ala-Lys-Hyp-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 34)
35 The title compound was prepared using essentially the same process as
the latter one
described in Example 1 above, except that Fmoc-DOPA(acetonide)-OH and Fmoc-4-
Hyp(tBu)-OH were used instead of Fmoc-Tyr(tBu)-OH and Fmoc-Pro-OH,
respectively,
in the relevant amino acid coupling steps to yield 3.79 g of crude title
compound.
41
CA 03150864 2022-3-10 RECTIFIED SHEET (
RULE 91 )
WO 2021/047648
PCT/CN2020/114828
Analysis showed a target peak that was eluted at 9.177 minutes with the
expected
molecular weight (MS: m/z 1215.7). The purity was 75.365%.
5 3.7 g of the crude product was then purified as described in Example 1
above to give
2.09 g of pure title compound after freeze-drying.
Example 6
Synthesis of Other Peptides
The following peptides were synthesised according to essentially the same
processes
as those described in Example 1 above, except that appropriate amino acids
were used
in the appropriate peptide coupling sequences:
Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 4; MS: m/z 1241.3);
15 Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 5; MS: m/z 1225.3);
Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 6; MS: m/z 1128.2);
Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 7; MS: m/z 1112.2);
Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (SEQ ID No: 8; MS: m/z 1215.3);
Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 9; MS: m/z 1199.3);
20 Ser-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 10; MS: m/z
1215.3);
Ser-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 11; MS: m/z 1199.3);
Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 12; MS: m/z 1312.4);
Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 13; MS: m/z 1296.4);
Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp (SEQ ID No: 16; MS: m/z 1113.1);
25 Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp (SEQ ID No: 17; MS: m/z 1097.1);
Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp (SEQ ID No: 18; MS: m/z 1000);
Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp (SEQ ID No: 19; MS: m/z 984);
Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA (SEQ ID No: 20; MS: m/z 1087.1);
Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr (SEQ ID No: 21; MS: m/z 1071.1);
30 Ser-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp (SEQ ID No: 22; MS: m/z 1087.1);
Ser-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp (SEQ ID No: 23; MS: m/z 1071.1);
Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp (SEQ ID No: 24; MS: m/z 1184.2);
Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp (SEQ ID No: 25; MS: m/z 1168.2);
Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp (SEQ ID No: 26; MS: m/z 1071.1);
35 Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp (SEQ ID No: 27; MS: m/z 1055.1); and
Ala-Lys-Pro-Ser-DOPA-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 30; MS: m/z 1215.3)
42
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
The following peptides are synthesised according to essentially the same
processes as
those described in Example 1 above, except that appropriate amino acids were
used
in the appropriate peptide coupling sequences:
3,4-dihydrocinnamic acid-Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No:
28);
5 Ala-Lys-Hyp-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 32); and
Ala-Lys-Hyp-Ser-DOPA-Hyp -Thr-DOPA-Hyp-Lys (SEQ ID No: 33).
Example 7
Cream Formulations I
Cream-based formulations comprising each of the peptides Lys-Pro-Ser-Tyr-Hyp-
Hyp-
Thr-DOPA-Hyp-Lys (SEQ ID No: 4); Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ
ID
No: 5); Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 6); and Lys-Pro-Ser-
Tyr-
Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 7) (see Example 6 above), were made as follows
15 using the following excipients, all of which were sourced from
Sinopharnn Chemical
Reagent Co. Ltd, Shanghai, China.
Sorbitan stearate (0.6 g), polysorbate-80 (1 g), silicone oil (0.5 g),
hexadecanol (2 g),
octanoic acid/decanoic acid glyceride (5 g), liquid paraffin (2 g), monostea
rate
20 glyceride (2 g) and vaseline (5 g) were mixed together and stirred. The
mixture was
heated to 85 C until the mixture had completely melted.
Methyl cellulose (0.5 g), glycerin (4 g), trehalose (0.5 g) and 64.97 g of
purified water,
were mixed together, stirred and heated to 85 C to form a homogeneous
colloidal
25 suspension.
30 mg of each of the four peptides were dissolved in 1 g of purified water.
The copolymer/water mixture was added to the sorbitan stearate-containing
mixture,
30 which was then quickly stirred using emulsification equipment for 5
minutes. The
resultant emulsion was cooled to 55 C, and then polyethylene glycol 200 (4 g),
phenoxy alcohol (0.3 g) and ethylhexyl glycerin (0.1 g) were added to the
mixture with
constant stirring until a uniform suspension was obtained. Then, the solution
containing
Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 4) was mixed in.
The resultant mixture was allowed to cool to room temperature to obtain the
finished
product.
43
CA 03150864 2022-3-10 RECTIFIED MEET (
RULE 91)
WO 2021/047648
PCT/CN2020/114828
This procedure was repeated for the other three peptides. Further, essentially
the same
procedure as that described above was employed to make cream-based
formulations
comprising 100 mg each of Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (SEQ ID No:
8); Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 9); Ser-Lys-Pro-Ser-
Tyr-
5 Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 10); and Ser-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-
Hyp-
Lys (SEQ ID No: 11) (see Example 6 above)
Example 8
Cream Formulations II
Cream-based formulations comprising each of the peptides Ala-Lys-Pro-Ser-Tyr-
Hyp-
Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 12); Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-
Lys (SEQ ID No: 13) (see Example 6 above); Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-
Hyp-
Lys (SEQ ID No: 14) (see Example 3 above); and Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-
Hyp-Lys (SEQ ID No: 15) (see Example 1 above), were made as follows using the
following excipients, all of which were sourced from Sinopharm Chemical
Reagent Co.
Ltd, Shanghai, China, unless otherwise specified.
Stearic add (2 g), glycerin monostearate (2 g) and hexadecanol (2 g) were
mixed
together and stirred. The mixture was heated to 850C until the mixture had
completely melted.
Ammonium acryloyldimethyltaurate/VP copolymer (0.13 g; Clariant Chemical Co.,
Ltd.,
Guangzhou, China), purified water (87.02 g). and sodium hydroxide (0.25 g)
were
25 mixed together at 850C and stirred to form a homogeneous colloidal
suspension. Then,
glycerin (5 g), phenoxyethanol (0.3 g) and ethylhexyl glycerin 0.1 g (latter
two
reagents both Shanghai Rayson Chemicals Co.,Ltd., Shanghai, China) were added
to
the mixture with constant stirring.
30 200 mg of each of the four peptides were dissolved in 1 g of purified
water.
The copolymer/water mixture and sorbitan stearate-containing mixture were
combined
as described in Example 7 above. The resultant emulsion was cooled to 550C and
then the solution containing Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ
ID
35 No: 12) was mixed in. Cooling to room temperature gave the finished
product.
The procedure was repeated for the other three peptides.
44
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Example 9
Lotion Formulations
Body lotions comprising 100 mg each of the peptides Lys-Pro-Ser-Tyr-Hyp-Hyp-
Thr-
DOPA-Hyp-Lys (SEQ ID No: 4); Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID
No: 5); Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 6); and Lys-Pro-Ser-
Tyr-
Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 7); Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys
(SEQ ID No: 8); Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 9); Ser-
Lys-
Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 10); and Ser-Lys-Pro-Ser-Tyr-Hyp-
Thr-Tyr-Hyp-Lys (SEQ ID No: 11) (see Example 6 above), were made as follows
using
the following excipients, all of which were sourced from Sinopharm Chemical
Reagent
Co. Ltd, Shanghai, China.
Hydroxypropyl methyl cellulose (HPMC; Cosmetic Grade, 0.1 g), hydroxyethyl
cellulose
(Cosmetic grade, 0.1 g), glucose, phenoxy alcohol (0.5 g) and purified water
(93.2 g)
were mixed together and heated to 850C with constant stirring until a
homogeneous
colloidal suspension resulted. The mixture was cooled to room temperature.
100 mg of each of the eight peptides were dissolved in 1 g of purified water.
The
solution containing Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 4)
was
added to the colloidal suspension and mixed together until the resultant was
mixed for
uniformly as the finished product.
The procedure was repeated for the other seven peptides. Further, essentially
the
same procedure as that described above was employed to make cream-based
formulations comprising 10 mg each of the peptides Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-
Thr-DOPA-Hyp-Lys (SEQ ID No: 12); Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys
(SEQ ID No: 13) (see Example 6 above); Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-
Lys
(SEQ ID No: 14) (see Example 3 above); and Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-
Lys (SEQ ID No: 15) (see Example 1 above).
Example 10
Gel Formulations I
Gel-based formulations comprising each of the peptides Lys-Pro-Ser-Tyr-Hyp-Hyp-
Thr-
DOPA-Hyp-Lys (SEQ ID No: 4); Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID
No: 5); Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 6); and Lys-Pro-Ser-
Tyr-
Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 7) (see Example 6 above), were prepared in
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
essentially the same way as described in Example 9, except that HPMC (1 g),
hydroxyethyl cellulose (1 g), glucose (5 g), phenoxy alcohol (0.5 g) and
purified water
(91.45 g) were mixed together and heated to 85 C with constant stirring prior
to
adding a solution of 50 mg of Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID
5 No: 4) in 1 g of purified water.
Complete mixing gave the finished product and the procedure was repeated for
the
other three peptides.
Example 11
Gel Formulations II
Gel-based formulations comprising each of the peptides Ser-Lys-Pro-Ser-Tyr-Hyp-
Hyp-
Thr-DOPA-Lys (SEQ ID No: 8); Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID
No:
9); Ser-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 10); and Ser-Lys-Pro-
Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 11) (see Example 6 above), were
prepared
using a similar process to that described in Example 10 above, but using the
following
excipients, all of which were sourced from Sinopharm Chemical Reagent Co. Ltd,
Shanghai, China.
Methyl cellulose (Cosmetic grade, 2.2 g), glycerol (11 g), propanecliol (11 g)
and
purified water (74.75 g) were mixed together and stirred for 10 hours to
obtain a
homogeneous colloidal suspension.
25 50 mg of Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (SEQ ID No: 8), pre-
dissolved
in 1 g of purified water was the added with mixing to obtain a uniform
finished product.
The procedure was repeated for the other three peptides.
Essentially the same procedure was employed to make gel formulations
comprising
150 mg each of the peptides Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ
ID No: 12); Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 13) (see
Example 6 above); Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 14)
(see
Example 3 above); and Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 15)
35 (see Example 1 above), except that 1 g of carbomer (Sinopharm Chemical
Reagent Co.
Ltd) was used in place of methyl cellulose, and 5 g of glycerol was used along
with
82.85 g of purified water.
46
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Example 11
Gel Formulations III
Skin care gel-based compositions based on the peptides Lys-Pro-Ser-Tyr-Hyp-Hyp-
Thr-DOPA-Hyp-Lys (SEQ ID No: 4); Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ
ID No: 5); Lys-Pro-Ser-Tyr-Hyp-Tbr-DOPA-Hyp-Lys (SEQ ID No: 6); and Lys-Pro-
Ser-
Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 7) (see Example 6 above) were made.
First sodium hyaluronate (0.2g; Sinopharm Chemical Reagent Co. Ltd was swelled
in
purified water (98.75 g) for 24 hours
50 mg of Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 4) pre-dissolved
in 1 g of purified water was added to the sodium hyaluronate gel and mixed
well to
obtain the finished product. The procedure was repeated for the other three
peptides.
Essentially the same procedure was employed to make gel formulations
comprising 20
mg each of the peptides Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (SEQ ID No:
8);
Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 9); Ser-Lys-Pro-Ser-Tyr-
Hyp-
Thr-DOPA-Hyp-Lys (SEQ ID No: 10); and Ser-Lys-Pro-Ser-Tyr-Hyp-Tbr-Tyr-Hyp-Lys
(SEQ ID No: 11) (see Example 6 above), except that, this time, 0.1 g of sodium
hyaluronate was added to 94.88 g of purified water prior to adding, in each
case,
separately pre-prepared solutions, each comprising 20 mg of each peptide in 1
g of
purified water, along with butanediol (2 g) and pentanediol (2 g) (both
Sinopharm
Chemical Reagent Co. Ltd), with mixing, to obtain the finished products.
Similarly, gel formulations were made from Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-
DOPA-
Hyp-Lys (SEQ ID No: 12); Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID
No:
13) (see Example 6 above); Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID
No:
14) (see Example 3 above); and Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID
No:
15) (see Example 1 above), as well as Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp
(SEQ
ID No: 16); Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp (SEQ ID No: 17); Lys-Pro-Ser-
Tyr-
Hyp-Thr-DOPA-Hyp (SEQ ID No: 18); and Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp (SEQ ID
No: 19) (see Example 6 above), in each case using 0.4 g of sodium hyaluronate
in 96.4
g (first four peptides) or 96.5 g (last four peptides) of purified water, and
adding 2 g
of butandiol (only) along with separately pre-prepared solutions comprising
200 mg of
each of the first four peptides, and 100 mg of each the last four peptides,
each of which
were dissolved in 1 g of purified water, to make eight separate gel products.
47
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Example 1.2
Skin Tonics
Skin tonics were made by dissolving the following amounts of each of the
following
5 peptides in the specified amount of purified water:
(a) Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 4); Lys-Pro-Ser-Tyr-
Hyp-
Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 5); Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys
(SEQ ID No: 6); and Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 7) (see
10 Example 6 above), 20 mg of each peptide in 99.98 g.
(b) Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (SEQ ID No: 8); Ser-Lys-Pro-Ser-
Tyr-
Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 9); Ser-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys
(SEQ ID No: 10); and Ser-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 11)
15 (see Example 6 above), 100 mg of each peptide in 99.9 g.
(c) Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 12); and Ala-Lys-
Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 13) (see Example 6 above)õ
mg of each peptide in 99.99 g
(d) Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 14) (see Example 3
above), 10 mg in 99.99 g.
(e) Ala-Lys-Pro-Ser-Tyr-Hyp-Tbr-Tyr-Hyp-Lys (SEQ ID No: 15) (see Example 1
above) ,
25 10 mg in 99.99 g.
(f) Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp (SEQ ID No: 16); Lys-Pro-Ser-Tyr-Hyp-
Hyp-Thr-Tyr-Hyp (SEQ ID No: 17); Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp (SEQ ID No:
18); and Lys-Pro-Ser-Tyr-Hyp-Tbr-Tyr-Hyp (SEQ ID No: 19) (see Example 6
above),
30 100 mg of each peptide in 99.9 g.
(g) Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA (SEQ ID No: 20); Ser-Lys-Pro-Ser-Tyr-
Hyp-Hyp-Thr-Tyr (SEQ ID No: 21); Ser-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp (SEQ
ID No: 22); and Ser-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp (SEQ ID No: 23) (see
35 Example 6 above), 40 mg of each peptide in 99.96 g.
(h) Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp (SEQ ID No: 24); Ala-Lys-Pro-Ser-
Tyr-Hyp-Hyp-Thr-Tyr-Hyp (SEQ ID No: 25); Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-
48
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Hyp (SEQ ID No: 26); and Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp (SEQ ID No: 27)
(see Example 6 above), 60 mg of each peptide in 99.94 g.
In each case, appropriate preservatives and/or moisturizers may be added to
the skin
5 tonics to provide a better skin feeling.
Example 1_3
Moisturizing Sprays
Moisturizing sprays based on the peptides Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp
(SEQ ID No: 16); Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp (SEQ ID No: 17); Lys-Pro-
Ser-Tyr-Hyp-Thr-DOPA-Hyp (SEQ ID No: 18); and Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp
(SEQ ID No: 19) (see Example 6 above), were made in the following way using
the
following excipients, all of which were sourced from Sinopharm Chemical
Reagent Co.
15 Ltd, Shanghai, China.
First 10 mg of each peptide were dissolved in 1 g of purified water to obtain
four peptide
skin tonics. Then, EDTA disodium (0.02 g), butanediol (1.5 g), arginine (0.02
g),
hexanediol (0.5 g) and purified water (96.95 g) were mixed together.
The peptide solution comprising Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp (SEQ ID
No:
16) was added to the resultant solution to obtain the finished product. The
procedure
was repeated for the other three peptides.
Example 14
Essences
Essences based on the peptides Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA (SEQ ID
No:
20); Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr (SEQ ID No: 21); Ser-Lys-Pro-Ser-Tyr-
30 Hyp-Thr-DOPA-Hyp (SEQ ID No: 22); and Ser-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-
Hyp (SEQ
ID No: 23) (see Example 6 above), were made in the following way using the
following
excipients, all of which were sourced from Sinopharm Chemical Reagent Co. Ltd,
Shanghai, China.
35 Sodium hyaluronate (0.5 g) and carbomer (0.04 g) were added to 98.36 g
of purified
water. After 24 hours, a swollen gel resulted.
49
CA 03150864 2022-3-10
WO 2021/047648
PCT/CN2020/114828
Each of the four peptides (100 mg) were dissolved in 1 g of purified water.
The
resultant solution comprising Ser-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA (SEQ ID No:
20)
was added to the sodium hyaluronate/carbomer mixture. Thorough mixing gave the
finished product.
The procedure was repeated for the other three peptides.
Example 15
Synthetic Peptides As a Peptide Glue
Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 14) (see Example 3 above)
was firstly dissolved in pure water (as well as aqueous solutions comprising
an acetate
buffer, and a phosphate buffers) at pHs between 2 and 8.
Various peptide mixtures were prepared with concentrations between 100 and 800
mg/g. After the peptide was fully dissolved, the clear solution was used as an
adhesive.
CA 03150864 2022-3-10
